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BIOCHEMICAL CHARACTERIZATION OF THE AXOLEMMAL MITOGEN FOR 
CULTURED SCHWANN CELLS 
ABSTRACT 
A dissertation submitted in partial fulf.illment of the 
requirements for the degree of Doctor of Philosophy at 
Virginia Commonwealth University 
Mark A. Decoster 
Virginia Commonwealth University 
Dr. George H. Devries 
The molecule(s) involved at the axon plasma membrane 
(axolemma) which causes Schwann cells to proliferate has 
been investigated by three biochemical techniques: l) 
Alkaline extraction of axolemma resulted in recovery of 95% 
of the mitogeni::: activity and 50% of the protein in the 
membrane-bound portion of the axolemma. 2) The axonal 
:mitogen for Schwann cells may be associated with heparan 
sulfate prcteoglycans at the axonal surface. Treatment of 
axolemma with heparitinase, which cleaves the glycosidic 
bonds of sulfated glycosaminoglycans, allowed mitogenic 
activity to be solubilized. 3) Treatment cf axolemma with 
heparin, a highly sulfated glycosaminoglycan analogous to 
heparan sulfate, resulted in a soluble mitogenic extract 
which had a higher specific mitogenic activity than the 
starting material. The results of these biochemical 
treatments support the model of an axonal mitogen for 
Schwann cells which is positively charged and bound to the 
negatively 
proteoglycans. 
charged portion of heparan sulfate 
xii 
A monoclonal antibody (1A5-?G3} was raised against the 
soluble mitogenic heparin extract of axolemma. The 
monoclonal antibody inhibited the mitogenicity of heparin 
extract as well as the mitogenicity of the starting 
axolemmal membrane. Non-specific monoclonal antibodies did 
not inhibit mitogenicity to as great an extent as 1A5-2G3. 
Mitogenic heparin extract was incubated with 1A5-2G3-
coupled or non-specific antibody-coupled Sepharose. 
Sepharose coupled with 1A5-2G3 removed significantly more 
mit6genic activity from the heparin extract than did non­
specific antibodies. Using immunoaffinity techniques with 
the monoclonal antibody and the soluble heparin extract 
should permit separation of the axoleEmal mitogen from 
other components of the axon plasma membrane. 
INTRODUCTION 
The characteristic morphology of Schwann cells was 
first described by Theodor Schwann 150 years ago (Schwann, 
1839). We now know that the Schwann cell is responsible 
for ensheathing and myelinating axons of the peripheral 
nervous system (PNS) , allowing for rapid trans:nission of 
neuronal signals in the form of saltatory conduction. The 
Schwann cell also demonstrates a dramatic ability to 
remyelinate axons 
Recruitment of the 
development and 
after 
necessary 
peripheral 
peripheral nerve damage. 
Schwann cells needed during 
nerve repair is largely 
accomplished by proliferation of Schwann cells. 
Current studies in our laboratory investigate the 
proliferative signals which the Schwann cell receives from 
the nervous system. In this introduction I will describe 
the proliferation of Schwann cells both in vivo and in 
vitro. The relevance of two different membrane mitogens 
(axolemma and myelin) for glial cells will be discussed. 
In addition, one of the few model systems for how membrane 
mitogens might work outside of the nervous system will be 
presented. This model system describes the mitogenic 
effect of bacterial membrane molecules on lymphocytes. 
Finally, the previous understanding of the axon as a 
1 
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mitogen to Schwann cells at the molecular level will be 
described as a preface to the presentation of our work, 
which characterizes the :nolecule ( s) involved in the axon 
plasma membrane in signalling Schwann cell proliferation. 
PROLIFERATION OF THE SCHWANN CELL IN VIVO 
The Schwann cell and neuron form a most intimate 
relationship in the peripheral nervous system: the main 
function of the Schwann cell being the support of the 
neuron by cytoplasmic ensheathment. This ensheathment is 
most extensive in the case of large axons; Schwann cells 
surround these. axons with compacted layers of their 
specialized plasma membrane called myelin. 
properties of myelin allow for rapid 
The insulating 
transmission of 
neuronal signals in larger axons via saltatory conduction. 
During embryogenesis the Schwann cell along with 
sensory and autonomic neurons derives from the neural 
crest. This origin of Schwann cells was supported by the 
early work of Harrison ( 1924) as well as the more recent 
work of Weston (1970) and LeDouarin (1982). Neural crest 
precursors migrate during the development of the peripheral 
nervous system. Tennyson 
of Schwann cells among 
(1965) demonstrated the presence 
the developing nerve cells of 
cranial and peripheral ganglia. As the peripheral nerve 
trunks form, Schwarm cells migrate outward along axonal 
fasciculi. During this migration and subsequent to it, 
3 
Schwann cells proliferate (Asbury, 1967). Studies by 
Aguayo et al. (1976) showed that reducing the number of 
developing neurons in peripheral tissues also reduced 
Schwann cell number. This result indicated that the neuron 
may be a primary stimulus for Schwann cell proliferation 
during axonal outgrowth. 
Initially, the limited number of Schwann cells 
surround many axons (Peters and Muir, 1959; Martin and 
Webster, 1973; Gamble and Breathnach, 1965). Ih the 
presence of these unensheathed axons, Schwann cell numbers 
increase greatly (Terry et al., 1974; Asbury, 1967). These 
proliferating Schwann cells segregate the axons (Peters and 
Muir, 1959; cravioto, 1965), establishing a 1:1. 
relationship with the largest axons (those which will be 
myelinated). Schwann cell proliferation terminates as the 
cells become committed to myelin formation and the 
connective tissue of the peripheral nerve develops more 
fully. 
The proliferation of Schwann cells during development 
of the peripheral nervous system is one of t,:o types 
observed in vivo; Schwann cells also proliferate during 
Wallerian degeneration of a peripheral nerve (Abercrombie 
and Johnson, 1946; Abercrombie and Santler, 1957; Joseph, 
1950; Bradley and Asbury, 1970). Earlier studies had shown 
that the progression of Schwann cell response to crush 
injury of a peripheral nerve included an increase in the 
number of Schwann cell nuclei distal to the site of injury 
4 
after 25 days, with a slight decline in number thereafter 
(Bradley and Asbury, 1970). The increase in Schwann cell 
number in response to injury of a peripheral nerve was 
found to be most extensive in myelinated nerves and least 
in thinly myelinated or unmyelinated nerves (Thomas, 1948; 
Joseph, 1950). More recently it has been shown that the 
increase in thymidine labelling of Schwann cell nuclei 
during Wallerian degeneration is greater in sciatic nerve 
(Bradley and Asbury, 1970; Friede and Johnstone, 1967) than 
in the unmyelinated cervical sympathetic trunk (Romine et 
al., 1976). 
Pellegrino et al. (1980, 1985) have presented evidence 
that axonal stimulation of Schwann cell division is 
important during 
(Pellegrino and 
nerve regeneration. These 
Spencer, 1985) demonstrated 
experiments 
that the 
arrival of a regenerating axon in vivo caused Schwann cells 
to undergo mitosis, presumably in a similar fashion to the 
Schwann cell contact with neurites regenerating from 
explanted dorsal root ganglia (Salzer et al., 1980). The 
experimental model used by Pellegrino and Spencer (1985) 
showed that the appearance of myelin formation ir. the 
regenerating nerve could be delayed by use of Mitomycin c, 
an antimitotic drug known to arrest Schwann cell division 
(Hall and Gregson, 1977; Lown, 1979). The effect of 
Mitomycin C appeared to be reversible however, since after 
long enough periods of time, myelin formation would appear 
in treated nerves. These results suggested that Schwann 
5 
cell proliferation may be necessary for myelination to 
occur. This interpretation may be more complicated, 
however, since Pellegrino and Spencer (1985) observed poor 
axonal regeneration in Mitomycin c-treated nerves. 
From this discussion it can be seen that there are two 
situations in which Schwann cell proliferation has been 
observed in vivo. In the first case, proliferation occurs 
in association with the axon during development of the 
nervous system. Secondly, in cases of Wallerian 
degeneration in the peripheral nervous system, the 
breakdown of myelinated nerves signals the Schwann cell to 
proliferate. This process is followed by introduction of 
regenerating axons to Schwann cells as damaged peripheral 
nerves extend processes. Schwann cell contact with 
regenerating axons also causes Schwann cell proliferation, 
allowing for the completion of nerve repair, including the 
production of myelin. 
It is the in vivo observations reviewed above which 
allowed a general description of the proliferative stages 
of Schwann cells. However, specific biochemical 
characterization of the proliferative response of Schwann 
cells to axons and to myelin has required the development 
of tissue culture techniques. I will review these 
techniques below, and indicate how they have brought us to 
the point of isolating and characterizing the axolernrnal 
mitogen for Schwann cells. 
6 
PROLIFERATION OF THE SCHWANN CELL IN VITRO 
The ability to identify Schwann ·cell mitogens using an 
in vitro system is possible in part because Schwann cells 
in culture proliferate at very low levels until stimulated 
with mitogens. Even in serum containing media, rat Schwann 
cells in culture are quiescent when isolated (Wood, 1976; 
Brockes et al., 1979; Salzer et al., 1980). 
As in vivo, when Schwann cells in culture are in 
contact with neurons they proliferate (Wood, 1976; Salzer 
et al., 1980, 1980a) . Membrane fragments from the axonal 
plasma membrane (axolemma) derived from cultured neurons 
are mitogenic to Schwann cells 
1980a, 1980b), indicating that 
in vitro (Salzer et al., 
a viable neuron is not 
necessary for axolemmal mitogenicity to be communicated to 
the Schwann cell. The studies of Salzer et al. (1980a) 
further showed that both trypsin and heat treatment could 
destroy the mitogenicity of neurite membranes to Schwann 
cells, implicating the protein nature of the neurite 
mitogen. In addition, axolemmal 
pheochromocytoma cells (Ratner et 
fragments from PC12 
al. , 1984) , brain 
(Devries et al., 1982; Cassel et al., 1982; Sobue et al., 
1983), and cerebellar granule cells (Mason et al., 1989) 
are mitogenic to Schwann cells, indicating that targeted 
mitogens for Schwann cells are not restricted to the 
peripheral nervous system (PNS). 
7 
Schwann cells will also proliferate in culture in 
response to myelin fragments (Cassel et al., 1982; Devries 
et al., 1982; Yoshino et al., 1984). Whereas the axolemmal 
mitogenic signal is relevant during development, myelin may 
serve as a mitogenic signal during Wallerian degeneration. 
A number of soluble factors have been identified as 
mi togenic to cultured Schwann cells. The protein glial 
growth factor (GGF), obtained from brain and pituitary 
(Raff et al., 1978; Brockes et al., 1980; Lemke and 
Brockes, 1984) causes Schwann cell proliferation. The 
activities of GGF from both bovine brain and pituitary are 
recovered from sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) at 31,000 daltons and have been 
shown to be basic in nature (Brockes, 1985). Glia 
maturation factor (GMF) (Bosch et al., 1984; Lim et al.,· 
1985), another protein purified from brain, is weakly 
mi togenic to Schwann cells. GMF has been purified from 
bovine brains to apparent homogeneity with a molecular 
weight of 14,000 daltons and an isoelectric point of pH 5.2 
(Lim et al., 1985). It is also known that agents which 
increase intracellular 3' ,5'-cyclic adenylate (cAMP) such 
as cholera toxin, 3-isobutyl-L-methyl-xanthine (IBMX), 
dibutyryl cyclic AMP and forskolin, are mitogenic to 
Schwann cells (Raff et al., 1978, 1978a; Porter et al., 
1986). Finally, extracellular components such as laminin 
(McGarvey 
Evercooren 
et 
et 
al., 
al., 
1984) and 
1982) 
fibronectin (Baron-Van 
promote Schwann cell 
8 
proliferation. Porter et al. (1987) showed that the effect 
of laminin and fibronectin could be due to an autocrine 
growth factor. Bunge has recently proposed that an 
autocrine growth factor made by Schwann cells could bind to 
the surface of axons, which would then present a suitable 
proliferative substrate for the Schwann cells (Bunge, 
1987). 
Although the above discussion of mitogens to Schwann 
cells may give the impression that many factors stimulate 
Schwann cell proliferation this is not the case; many known 
mitogens for other cell types fail to cause Schwann cell 
proliferation. 
growth factor 
Concanavalin A, phytohemagglutinin, 
(NGF) I epidermal growth factor 
nerve 
(EGF), 
acetylcholine, norepinephrine, insulin, proinsulin, 
dexamethasone, prostaglandin PGF2 a! the calcium ionophore 
A23187, arachidonic acid, ouabain, tubulin and trypsin were 
tested by Salzer and Bunge (1980) for mitogenicity toward 
Schwann cells. None of these substances were mitogenic to 
Schwann cells. Raff et al. (1978) tested luteotropic 
hormone, follicle-stimulating hormone, thyroid-stimulating 
hormone, growth hormone, adrenocorticotropic hormone, 
vasopressin, prolactin, luteinizing hormone, prostaglandin 
E1, and isoproterenol at concentrations up to 50 i-g/ml and 
found no mitogenic effect on Schwann cells. Devries et al. 
(1983) added gangliosides (mixed, from bovine brain), 
heparin, cyclic guanosine monophosphate (cGMP), myelin 
basic protein, and rat liver microsomes to Schwann cells 
9 
and found none of these substances mitogenic. Salzer et 
al. (1980b) found that the particulate fractions of 
fibroblasts (3T3 cells), and several neuroblastomas were 
not mitogenic to Schwann cells. 
Recently, Ratner et al. (1988) have shown that 
embryonic rat brain membranes are mitogenic to Schwann 
cells. Ratner et al. also showed that basic fibroblast 
growth factor (bFGF) is mitogenic to Schwann cells in 
contrast to the studies of Salzer and Bunge (1980), who 
found that fibroblast growth factor (FGF) was not mitogenic 
to Schwann cells. Ratner et al. ( 1988) found that bFGF 
caused approximately 10 times less maximal proliferation of 
Schwann cells than a neuronal source, using a maximal dose 
of bFGF at 80 ng/ml. Salzer and Bunge (1980) however, 
found that FGF at doses as high as 10 1,g/ml caused no 
Schwann cell proliferation. 
The above discussion demonstrates that the in vitro 
studies of Schwann cell mitogens support observations made 
in vivo. Schwann cells undergo proliferation during two 
general situations in the peripheral nervous system: 1) 
during development in response to axonal contact and 2) 
during Wallerian degeneration and the events consequent to 
it (release of myelin fragments, which are mitogenic to 
Schwann cells in vitro and stimulus from the regrowing 
axon). In addition, tissue culture studies have revealed 
the mitogenic effect of soluble growth factors such as GGF 
and GMF on Schwann cells; the role of these growth factors 
10 
during normal development of the nervous system or in cases 
of injury is not yet clear. 
RELEVANCE OF MEMBRANE MITOGENS FOR GLIAL CELLS 
Mitogens for Schwann cells are isolated from two 
sources in our laboratory: myelin and axolemma. Although 
the work in this thesis describes isolation and 
characterization of the axolemmal mitogen for Schwann 
cells, 
myelin 
I will review our current understanding of the 
mitogen for Schwann cells, and why it appears 
distinct from the axolemmal mitogen. 
As described above, myelin is a relevant mitogen for 
Schwann cells during degenerative states such as Wallerian 
degeneration. Since myelin is formed by the Schwann cell, 
it serves as a mitogenic signal after development is 
complete, when fully myelinated axons are injured. 
The work of Beuche and Friede (1984) demonstrated the 
importance of macrophages in removing myelin debris from 
sites of nerve degeneration. The work of Yoshino et al. 
(1984) showed that the mitogenicity of axolemma and myelin 
to cultured Schwann cells was distinct: the shape of the 
dose response curve for [ 3HJthymidine incorporation by 
Schwann cells in response to axolemma and myelin was 
different, and the lysosomal inhibitor ammonium chloride 
blocked the mitogenicity of myelin, while not affecting the 
mitogenicity of axolemma to Schwann cells. 
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Bigbee et al. ( 1987) found that macrophages were 
present in Schwann cell cultures isolated by the method of 
Brockes et al. (1979). Baichwal et al. (1988) demonstrated 
that conditioned medium from cultured peritoneal 
macrophages which had phagocytosed myelin was mitogenic to 
Schwann cells. Conditioned media from macrophage cultures 
given axolemma was not mitogenic to Schwann cells. Recent 
results (Baichwal and Devries, Science, submitted) indicate 
that the mitogenicity of myelin processed by macrophages 
may be related to myelin basic protein. 
The mitogenicity of myelin to Schwann cells seems to 
be unique in a number of respects. First, as a product of 
the glial cell, myelin will serve as a proliferative signal 
after development is complete and axons are already fully 
ensheathed; the primary role of the axonal mitogen seems to 
be during development. Second, the mitogenicity of myelin 
to Schwann cells is mediated by macrophages, and may be due 
to a polypeptide derived from the degradation of myelin 
basic protein; the mitogenicity of axolemma to Schwann 
cells is not mediated by macrophages. 
It is of further interest to note that whereas 
axolemma can stimulate oligodendrocytes to proliferate 
( Chen and De Vries, 
membranes do not 
(Chen and Devries, 
1989) as well as Schwann cells, myelin 
cause oligodendrocytes to proliferate 
1989) . The differential response of 
oligodendrocytes and Schwann cells to myelin may be due to 
the absence and ·presence of macrophages in the respective 
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cultures; this may also correlate with the observations in 
vivo: glial proliferation and repair in response to nerve 
damage in the central nervous system (CNS) is much less 
extensive than is the case for the peripheral nervous 
system. 
A recent observation of Schwann cell proliferation in 
culture indicates that these cells may make an autocrine 
growth factor (Porter et al., 1987}. Bunge proposes 
(Bunge, 1987) that the axon surface may serve as a 
substrate to which an autocrine growth factor may bind. 
The axon may be an essential substrate for the autocrine 
growth factor to transmit its mitogenic signal to the 
Schwann cell. If the idea of the axon as a substrate for 
an autocrine growth factor is true, similar arguments could 
be made to explain why axolemma is mi togenic to 
oligodendrocytes. Another possibility is that an autocrine 
growth factor for glial cells might be related to myelin 
basic protein. As described above, recent results from our 
laboratory indicate that the mitogenicity of myelin to 
Schwann cells mediated by macrophages may be due to the 
presence of myelin basic protein. Since myelin is a 
product of 
proteins and 
mitogen and 
glial cells, similarities between myelin 
an autocrine factor may exist. The myelin 
autocrine factor are thus distinct from an 
axolemmal mitogen: myelin and autocrine factors are 
products of the glial cell; an axolemmal mitogen for glial 
cells would presumably be produced by the neuron, which 
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would then be an appropriate signal for glial 
proliferation. 
Having discussed the relevance of other membrane 
mitogens for glial cells, I will now concentrate on the 
mitogen studied in this thesis: the axonal surface as a 
mitogen for glial cells. As already mentioned, the axon 
surface provides a mitogenic signal to Schwann cells during 
development, and may also do so during nerve regeneration. 
A similar situation most likely exists for 
oligodendrocytes, at least in vitro. We now know that 
direct contact wi�h axons is required for oligodendrocytes 
to proliferate in culture (Wood and Bunge, 1986), and that 
axolemma fragments are also mitogenic to these cells (Chen 
and Devries, 1989). Why axonal damage leads to Schwann 
cell proliferation and remyelination but not a similar 
response from oligodendrocytes is not yet clear. 
The relevance of an axonal plasma mel:lbrane mitogen for 
glial cells is clear. During ensheathment of axons by glia 
during development, too few cells exist to organize all of 
the axons. Axonal stimulation of glial cell proliferation 
might then be a signal of recruitment for glial cells to 
complete the organizational ensheathment of axons. 
In the peripheral nervous system, commitment of one 
Schwann cell to one axon leads to differentiation (myelin 
formation) with the concomitant cessation of Schwann cell 
proliferation. One or more axons may be ensheathed by 
Schwann cells not forming myelin, but this too may be a 
14 
commitment to differentiation and thus cessation of cell 
proliferation. 
A similar concept of_ the axon as a stimulus for glial 
proliferation in the CNS is complicated by the fact that 
oligodendrocytes myelinate many axons (Bunge, 1968; Peters 
et al., 1976). The axonal surface may present a stimulus 
for recruiting more oligodendrocytes to help organize the 
central nervous system. However, commitment of an 
oligodendrocyte to myelination of one axon may not prevent 
it from prolife::-ating (Skoff et al., 1976). Furthermore, 
the importance of an axonal signal for oligodendrocyte 
proliferation in regulating CNS organization may be 
mediated by astrocytes. Astrocytic prosesses subdivide 
neurite bundles, and may serve as a supportive framework 
for oligodendroglial differentiation (Webster et al., 
1981). Astrocytes also express bFGF (Ferrara et al., 1988) 
which is mitogenic to oligodendrocytes (Eccleston and 
Silberber, 1985); thus, astrocyte-derived bFGF could play 
an important role in the development and differentiation of 
oligodendrocytes, and in the synthesis of the myelin 
sheath. 
Another complexity in the ability for the axon to 
stimulate glial cell proliferation lies in its apparent 
lack of specificity between the CNS and PNS. Axonal 
sources from the PNS (Devries et al., 1982) and CNS 
( De Vries et al. , 1982; Ratner et al. , 1987) both cause 
Schwann cell proliferation. Both CNS (Chen and Devries, 
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1989) and PNS (Wood and Williams, 1984; Wood and Bunge, 
1986) neuronal sources are mitogenic to oligodendrocytes. 
Further, granule cell neurons from the cerebellum cause 
Schwann cells to proliferate but not oligodendrocytes 
(Mason et al., 1989a). Granule cells are not ensheathed by 
any glia once development is complete, yet the type of 
mitogenic signal that they provide to Schwann cells appears 
similar to that of myelinated neurons (Mason et al., 1989). 
Less well understood is the role that the surface of 
the axon may have in causing glial proliferation in 
regenerative situations. It can easily be envisioned that 
the bare axonal surface of regenerating axons may provide a 
mi togenic signal to Schwann cells similar to the signal 
encountered during development. Pellegrino and Spencer 
(1985) propose that regrowing axons do indeed provide a 
mi togenic signal to Schwann cells. The work of Brockes 
(1985) suggests that Schwann cells may require axonal 
signals to proliferate in blastema formation of amphibian 
li� regeneration. The blastema is a growth cone composed 
of undifferentiated cells which arises at the site of 
amputation. The amputated limb is regenerated by 
proliferation and morphogenesis of the blastemal cells. In 
amphibian limb regeneration, peripheral nerves appear to 
stimulate the division of blastemal cells. The work of 
Brockes (1985) indicates that this peripheral nerve supply 
may provide a source of cells for the blastema from the 
Schwann cells of the nerve sheath. 
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In light of our limited understanding of nerve 
regeneration we can only make general statements about the 
observations that appear to hold true. The peripheral 
nervous system responds to injury with a substantial degree 
of remyelination by the Schwann cell; there appear to be 
few circumstances where deficiency of Schwann cells 
contributes to the failure of remyelination after a 
peripheral demyelinating event (Bunge, 1982). In contrast 
to the PNS, the CNS, particularly as characterized in 
multiple sclerosis, fails to remyelinate sufficiently for 
full recovery of function. What prevents remyelination 
after injury in the CNS remains unclear. 
It is clear from the above discussion that the surface 
of the axon provides a proliferative signal for glial cells 
which support neurons. This proliferative signal is 
developmentally relevant in that it recruits the necessary 
glial cells for ensheathment and organization of axons. 
The bare surface of the axon may also present a 
proliferative signal to glial cells during regenerative 
events. 
The molecular identity of the axonal mitogen for glial 
cells is not 
between glial 
known. 
cells 
Considering the 
and axons, the 
close apposition 
mitogenic signals 
communicated to glia may be novel in character. As an 
introduction to the possible molecular characteristics of 
the axonal membrane-bound mitogen for glia, I will review 
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the few model systems that exist for membrane mi togens 
outside the nervous system. 
MODEL SYSTEMS FOR MEMBRANE MITOGENS (NON-NEURONAL) 
Mitogenic signaling via the close apposition of glial 
cell and axon is 
already described. 
mi togens outside 
one type 
One of 
of the 
of mitogenic membrane system 
the few cases of membrane 
nervous system exists for 
lymphocytes. A review of membrane mitogens for lymphocytes 
will show that even for these cells, little is known about 
the molecular identity or mechanism of action of membrane 
molecules causing proliferation. 
Concanavalin A (Con A) is a well known plant lectin 
that is mitogenic to lymphocytes. 
this lectin in the soluble form 
Many investigators use 
to study lymphocyte 
et al. (1979) showed proliferation. Studies by Kazura 
however, that Con A-pretreated human monocytes would bind 
human lymphocytes and cause the mitogenic transformation of 
these lymphocytes in the absence of soluble Con A. This 
result implied a similar role for lymphocyte-monocyte 
interaction as the work of Rosenstreich et al. (1976) who 
showed that 
proliferates 
Con A only 
a 
in 
when 
purified guinea-pig T-cell population 
response to phytohaemagglutinin (PHA) or 
reconstituted with macrophages. '!'hese 
results added to the increasing evidence that the monocyte­
macrophage is necessary for optimal antigen- and mitogen-
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induced lymphocyte transformation (Cline and Swett, 1968; 
Hedfors et al. , 197 5; Lohrmann et al. , 197 4; Seeger and 
Oppenheim, 1970). The monocyte thus serves as a substrate 
for mitogens which are then presented to lymphocytes, 
causing the lymphocytes to proliferate. The monocyte as a 
substrate for mitogenic PHA and Con A which then is 
presented as a mitogenic signal to the lymphocyte could be 
looked upon as a model similar to that outlined by Bunge 
(1987) for the axon and glial cell: an autocrine growth 
factor released by the Schwann cell requires presentation 
by the axon for the mitogenic signal to be effectively 
transmitted to the Schwann cell. 
Takada et al. ( 1981) demonstrated that cytoplasmic 
membranes of Staphylococcus aureus L-forms were mi togenic 
to human lymphocytes. The membrane mi tog en ( s) was 
characterized as resistant to trypsin, although it was 
partially solubilized by this treatment. Mitogenic 
activity of the Staphylococcus aureus membranes to human 
lymphocytes was not extracted 
though the chloroform-methanol 
with chloroform-methanol, 
soluble fraction was 
strongly mitogenic to murine splenocytes. Previous work by 
Takada et al. (1980) had shown that the mitogenicity of 
membranes from the same source as above for B-cells of mice 
and guinea pigs was resistant to heating at 100° C for 10 
min. These results indicated that the mitogenic activity 
of Staphylococcus aureus membranes may be due to a lipid or 
carbohydrate molecule. Takada et al. (1981) theorized that 
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the membrane mitogen (s) they characterized was similar to 
the mycoplasma mitogens acting on B-cells of mice and rats 
described by Naot et al. (1977, 1978, 1979). The molecular 
identity of these mitogens is not known. 
A membrane mitogen from Escherichia coli which causes 
human B lymphocyte proliferation has recently been 
described (Ponniah et al., 1989) in greater molecular 
detail than the mitogens discussed above. Escherichia coli 
is known to produce a mannose-sensitive adhesin molecule 
that has been shown to be associated with type 1 fimbriae 
expressed at the surface of the bacteria (Salit and 
Gotschlich, 1977; Ofek and Beachey, 1978). These adhesin­
bearing fimbriae mediate specific attachment of�- coli to 
mannose-containing receptors on the surface of human 
epithelial cells, macrophages, and polymorphonuclear cells 
(Ofek et al., 1977; Bar-Shavit et al., 1977). The work of 
Ponniah et al. (1989) suggests that the adhesin molecule 
stimulates a rnitogenic response in B cells, and that other 
structural components of the fimbriae are responsible for 
evoking a mitogenic response in T cells. Various reports 
suggest that the adhesin may consist of a combination of 
two proteins: the 29-kiloDalton (kDa) product of the fimH 
gene and the 14-kDa product of the fimG gene (Klemm and 
Christen, 1987; Abraham et al., 1987; Maurer and Orndorff, 
1985). More recent results indicate however, that the 
adhesive function night be due solely to the 29-kDa protein 
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(Maurer and Orndorff, 1987; Hanson and Brinton, 1988; 
Abraham et al., 1988). 
From the above discussion we can gain an appreciation 
of the state of understanding about membrane mitogens 
outside the nervous system: activities have been observed 
for a number of membranes on different cells, but molecular 
identities and mechanisms for these mi togenic actions are 
yet to be elucidated. At least for the case of adhesins in 
�- coli, and their mitogenic activity to lymphocytes, 
molecular understanding is clearer: specific gene products 
have been isolated as likely mediators in the mitogenic 
signal. It is of interest to note that a general theme 
appears important when considering membrane-bound mitogens: 
recognition is essential for proliferation. The binding of 
bacterial membranes to lymphocytes, possibly by the adhesin 
molecules described above, appears to be required for 
recognition of these membranes as mitogenic to lymphocytes. 
Binding of axolemma membranes to Schwann cells also 
correlates with the mitotic response to these membranes 
(Sobue and Pleasure, 1985). Once again, recognition leads 
to proliferation. Thus, understanding the identity and 
mode of action of membrane mitogens outside the nervous 
system may help us elucidate signals transduced by glial­
axcn association. Below I will review the molecular 
understanding cf axolemma as a membrane mitogen for glia 
which led to the work in this thesis. 
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RATIONALE OF THE PROJECT 
Although Schwann cells normally function in the 
peripheral nervous system, an abundant source of mitogenic 
activity for Schwann cells has been found in adult rat 
brain axolemma (Yoshino et 
identity of the axolemmal 
al., 1984). The molecular 
membrane mitogen for Schwann 
cells is not known. To further understand the interaction 
between Schwann cell and axon we thus continued previous 
studies in our laboratory using this axolemmal membrane. 
Devries et al. (1982) showed that the mitogenic effect 
of axolemma is heat and trypsin labile, suggesting that the 
mitogen may .be a protein. The work of Cassel et al. (1982) 
supported the idea that the axolemmal mitogen for Schwann 
cells is a protein, and this work indicated that the 
protein may be integrated in the axonal membrane; attempts 
to dissociate the mitogenic activity from the membrane were 
variable. Salzer et al. (1980a) showed that after treating 
neurites in culture with trypsin, loss of mitogenicity to 
Schwann cells due to the enzymatic treatment could be 
recovered with time. This indicated that the neurites were 
able to regenerate the mitogenic signal after trypsin 
treatment; the process appeared to require 1-2 d. The work 
of Sobue and Pleasure (1985) demonstrated that the adhesion 
of axolemmal fragments to Schwann cells was closely linked 
to axolemmal induction of Schwann cell mitosis. This 
result showed that axolemmal fragments, like neurites 
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(Salzer et al., 1980a), require contact with the Schwann 
cell to transmit a mitogenic signal. Studies in our 
laboratory (Meador-Woodruff et al., 1985) further supported 
the idea that the mitogenicity of axolemma may be 
transduced at the Schwann cell surface. 
The molecular architecture of the neuronal surface 
necessary for mitogenicity to Schwann cells began to be 
investigated by Ratner et al. (1985). Ratner et al. (1985) 
demonstrated that blocking proteoglycan synthesis in 
neurites destroys the mitogenic effect of neurites towards 
Schwann cells. Treatment of neurites with heparitinase, 
an enzyme which cleaves the glycosidic bonds of sulfated 
glycosaminoglycans, also depleted the mitogenicity of -the 
treated neurites. In addition, membranes prepared from 
neurons treated as above were also depleted in mi togenic 
activity to Schwann cells. However, Ratner et al. (1986) 
showed that castanospermine, which specifically blocks 
essential steps in the processing of asparagine-linked 
oligosaccharides, does not affect the ability of axons to 
stimulate Schwann cell proliferation. These results 
suggested that the neuronal mitogen may be associated with 
sulfated proteoglycans at the membrane surface of the axon; 
presentation of the mitogenic signal to Schwann cells 
required this proteoglycan architecture. Recent results by 
Ratner et al. (1988) demonstrated that mitogenic activity 
for Schwann cells could be extracted from embryonic brain 
tissue, and that this mitogenic activity bound to heparin. 
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The molecular identity of this mitogenic factor is not yet 
known, but it does not appear to be b:FGF (Ratner et al.·, 
1988). 
SUMMARY 
The mitogenic signal which the axon transmits to the 
Schwann cell is relevant in vivo during development and 
during the regeneration of peripheral nerves. Mitogenic 
signals from the axon to the Schwann cell recruit the 
necessary glia needed for ensheathment and myelination of 
nerves during the early organization of the nervous system. 
The regrowth of unensheathed axons after peripheral nerve 
damage presumably provides similar proliferative signals 
that permit the extraordinary regenerative capacity of 
Schwann cells. 
Tissue culture techniques have allowed initial 
biochemical characterization of the proliferative signal 
contained on the axon for glial cells. The relevance of a 
mitogenic signal on the axonal surface would seem to exist 
for both PNS and CNS glia; in vitro experiments have begun 
to investigate proliferation in both systems. 
The intimate relationship that requires glia to 
ensheath or myelinate axons may utilize novel proliferative 
signals. Many of the mitogens characterized to date are 
soluble in nature. Of the few cases of membranous mitogens 
24 
studied outside the nervous system, molecular identities 
and mechanisms of action are still unclear. 
The molecular architecture required for axonal 
presentation of a mitogenic signal to glial cells has just 
begun to be investigated; the work of Ratner et al. (1985) 
has demonstrated the importance of proteoglycans in 
presentation of this signal to Schwann cells. Although the 
molecular identity of the axonal mitogen for Schwann cells 
is not known, previous studies had shown that the mitogen 
was heat and trypsin labile (Devries et al., 1982) 
suggesting the protein nature of the mitogen. Bunge (1987) 
had suggested that the axonal surface might serve as a 
substrate to which a Schwann cell autocrine factor might 
bind; once bound to the axon, the 2.utocrine factor would 
then present a mitogenic signal to Schwann cells. The most 
recent work of Ratner et al. (1988) suggested that an 
embryonic brain neuronal mitogen for Schwann cells was 
peripheral rather than intrinsic to the membrane, since 
mitogenic activity to Schwann cells could be bound to 
heparin. These studies have not provided an answer to what 
molecule(s) on the axon cause Schwann cell proliferation. 
The work in this thesis presents biochemical clues which 
unmask the identity of the axonal membrane mitogen for 
Schwann cells. 
MATERIALS AND METHODS 
--Preparation of Schwann Cell Culture: 
Schwann cells were isolated from rat sciatic nerves by 
a modification of the method described by Brockes et al. 
(1979). The nerves were obtained from Sprague-Dawley rats 
aged 1-3 days. Rat pups were placed in an air-tight jar 
containing ethyl ether (for anesthesia). Each rat pup was 
anesthetized for approximately 4 minutes. Anesthetized rat 
pups were removed from the jar and decapitated. Rat pup 
bodies were pinned to a Styrofoam board in a horizontal 
laminar flow hood. Rat pup bodies were sprayed with 95% 
ethanol to remove surface bacteria. Dissections were 
carried out in the hood using an American Optical 
dissection microscope. As sciatic nerves were removed, 
they were placed in a sterile beaker containing 
of HE, and the nerves in the beaker 
temperature in the hood during the 
Dissection lasted no longer than 90 
medium consisted of 90 parts Dulbecco's 
approximately 10 ml 
were kept at room 
dissection procedure. 
HE minutes. 
modified 
water, 
Eagle 
2 parts 
,nedium (DME), 10 parts sterile distilled 
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ethanesulfonic acid 
mM N-2-Hydroxyethyl-piperazine-N'-2-
(HEPES) buffer, and O. 1 parts Pen-
25 
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Strep. Careful efforts were made to remove sciatic nerves 
free of attached muscle. 
Typically, 40-80 sciatic nerves were dissected per 
preparation. The pooled nerves were transferred by pasteur 
pipette to a 50 ml sterile flask. HE medium was removed 
from the flask by pasteur pipette without taking up nerves; 
2.5 m: of HE was then added to the flask along with 300 µl 
of Serva collagenase (0.3%) which had been dissolved in HE. 
Collagenase treatment of the nerves was carried out in the 
flask in a water bath at 37° c while shaking for 15 min. 
Medium was removed from the flask by pasteur pipette, 
avoiding taking up intact sciatic nerves. HE and 
collagenase were added back to the flask for a second 
treatment as described above. Medium was again removed 
from the flask, avoiding taking up intact pieces of sciatic 
nerve. At this point small, dissociated pieces of nerve 
were removed with the medium, as these often consisted of 
muscle and connective tissue not associated with intact 
nerves. 
HF medium was added to the flask of nerves in the 
amount of 3.5 ml. HF medium consisted of 90 parts DME, 10 
parts fetal calf serum, 1. 4 parts 7. 5% NaHco3, and O. 1 
parts Pen-strep. Nerves were then triturated by pasteur 
pipette for 5-10 min, until HF medium became cloudy with 
released cells. An additional 3. 5 ml of HF medium was 
added to the flask, and the above trituration step 
repeated. Triturated nerves were then passed through Nitex 
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209 polyamide nylon fiber to remove nerve pieces; medium 
containing cells was collected into a 15 ml centrifuge tube 
and centrifuged at 200 x g. HF medium was removed from the 
pelleted cells, and then 1 ml of HF added back to the 
centrifuge tube. Pelleted cells were resuspended in the 1 
ml of HF by vortexing. Vortexing was continued until the 
cell pellet was uniformly dispersed. 
Ten µl of the resuspended cells was used on a 
hemacytometer to calculate the cell density obtained. 
Cells were then plated onto 100 mm diameter pyrex petri 
dishes in 10 ml of HF at a cell density of approximately 3 
x 106 cells/dish. 
The cells were maintained in HF at 37 ° C in the 
presence of 10% co2. 
arabinoside (AraC) , 
concentration of 1 
was 
X 
One day after plating, cytosine 
added to the cell culture at a 
10-5 M in order to reduce the 
fibroblast contamination. After three days of treatment, 
Arac was removed and 10 ml of HF added to the cultures. 
Three days later, the last traces of fibroblast 
contamination were eliminated by complement mediated lysis 
using anti-Thy 1.1. The hybridorr.a clone TIB-103 was 
obtained by our lab from the American Type Culture 
Collection, and was grown in HF to produce anti-Thy 1. 1 
supernatant. Thy 1. 1 has been shown to be an antigenic 
marker for fibroblasts, and can thus be used for complement 
mediated lysis of these cells. 
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Schwann cell cultures were treated with 10 ml of TIB-
103 supernatant + 200 µl of Cappel Rabbit complement per 
dish. Rabbit complement was reconstituted from the 
lyophilized powder with 1 ml of sterile water/bottle; each 
lot of complement had been tested by manufacturer for the 
ability to lyse red blood cells. Reconstituted complement 
was stored at -20° c and reused only once to avoid 
inactivation by freezing-thawing. TIB-103 supernatant and 
complement remained on Schwann cell cultures for 
approximately 1 hour at 37 ° C in a  10% co2 incubator. The 
complement containing medium was then removed from treated 
cultures and each petri dish of Schwann cells treated with 
5 ml of Saline I + 250 µl of 0.4% 
ethylenediaminetetraacetate (EDTA) to remove cells from the 
dish. Petri dishes were swirled for 5-10 min or until 
cells had lifted from the plate as observed by microscope. 
Cells were removed from each petri dish and put in a 
separate 15 ml centrifuge tube for each dish. Each dish 
was rinsed with 5 ml of HF and this medium added to the 
corresponding centrifuge tube for that dish. Each petri 
dish was examined by microscope to ens�re cells were 
removed. Cells were then centrifuged in each tube at 200 x 
g for 5 min. 
The supernatant from each tube was removed by pasteur 
pipette, with care being taken not to disturb the cell 
pellet. One ml of HF was added back to each centrifuge 
tube and the cell pellets resuspended via vortexing. Cell 
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densities were determined be counting 10 µl of the cell 
suspension from each tube in a hemacytometer. The cells in 
each tube were then diluted to 80,000 cells/ml by addition 
of HF to each tube. The cells from each tube were then 
aliquoted into separate 96 well microtiter plates. Each 
well received 100 µl (8,000 cells). Cells were maintained 
in 10% CO2 incubators at 37
° C for at least 1 day before 
the addition of mitogens. 
--Isolation of Axolemma- and Myelin-Enriched Fractions: 
Axolemma- and myelin-enriched fractions were prepared 
as described by Yoshino et al. (1984). Adult rat brainstem 
white matter was removed from decapitated Sprague Dawley 
rats. After removal from the brain, each brainstem was 
placed in a beaker of homogenizing medium on ice. 
Homogenizing medium consisted of 1 M sucrose, 150 mM NaCl, 
and 0.02% sodium azide in 10 mM N-tris-hydroxy­
methyl(methyl-2-aminoethane-sulfonic acid) (TES), pH 7.4. 
After collecting all brainstems, homogenizing medium was 
drained, and the wet weight of brainstems determined. 
Brainstems were segregated into 1 gram portions. Each 
portion of brainstems was minced until homogeneous with a 
75 mm microtome blade on a mincing plate en ice. 
Each 1 gram portion of minced brainste� was 
transferred to a 
homogenizing medium. 
Dounce homogenizer with 37 ml of 
Tissue was homogenized by making 6 
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passes with the loose pestle (A), followed by 4 passes with 
the tight pestle (B). Each homogenate was transferred to a 
polyallomer centrifuge tube and using the SW27 rotor, 
centrifuged at 25,000 rpm (82,000 x g) for 20 min at 4° c. 
This procedure generated a floating pad of myelinated 
axons, a supernatant, and a pellet. 
The floating pad was removed from the centrifuge tube 
by breaking the interface between tube and tissue by 
squeezing the tube gently and flipping the pad into a 
Dounce homogenizer with a prewetted spatula. Floating pads 
from up to 6 tubes were consolidated into one homogenizer 
and homogenized in 35 ml of 10 mM TES, pH 7.4, by making 10 
passes with the tight pestle. This procedure was done to 
disrupt the myelinated axons osmotically and mechanically. 
Sucrose gradients were prepared using 10% sucrose 
(w/w), 0.02% sodium azide in 10 mM TES, pH 7.4 and 40% 
sucrose (w/w) , O. 02% sodium azide in 10 mM TES, pH 7. 4. 
Continuous gradients were prepared using 34 ml of 10% 
sucrose and 17 ml of 40% sucrose for each gradient; 
gradients were collected into 38.5 ml cellulose tubes. One 
gradient was prepared for each gram of brainstem tissue 
isolated. Gradients were stored upright on ice during 
preparation of membranes. 
Floating pad homogenates were l�yered evenly on top of 
each sucrose gradient. Approximately 3 ml of homogenate 
was applied to each gradient. The liquid level of each 
gradient tube was brought to about 2 ml from full by the 
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addition of 10 mM TES. Sucrose gradient tubes were loaded 
onto a SW27 rotor and centrifuged at 82,000 x g overnight 
at 4° c. 
Two ml fractions were collected by puncturing the 
bottom of the gradient tubes. The sucrose density of each 
fraction was determined by refractometer. Axolemma 
fractions were assayed for acetylcholinesterase activity. 
Typically, axolemma was collected at sucrose densities of 
28-32% and myelin collected at densities of 16-19%. 
Fractions pooled as axolemma were found to have the highest 
specific activity for acetylcholinesterase. 
Pooled fractions were transferred to sterile Ti 35 
centrifuge tubes. Centrifuge tubes were sterilized by 
spraying with 95% ethanol; the tubes were then allowed to 
dry in a sterile hood until all the ethanol had evaporated. 
No more than half of each tube was filled with a particular 
fraction; when a given fraction was greater than half the 
volume of the tube, the fraction was distributed to another 
centrifuge tube. Each centrifuge tube was then filled to 
the shoulder with sterile isotonic saline and inverted 
several times to mix the fraction and saline. This step 
served as a method for washing each fraction and removing 
azide. Ti 35 tubes were centrifuged for 1 hour at 70,000 x 
g at 4 0 C to obtain membrane pellets. 
Supernatants were decanted from membrane pellets in a 
sterile hood using sterile pipets. Pellets were 
resuspended in sterile isotonic saline by trituration until 
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homogeneous, in as concentrated a form as possible. 
Resuspended pellets were aliquoted into sterile microfuge 
tubes, 500 µl of membrane added to each tube. Tubes were 
stored at -70° C and thawed before use. Membranes were not 
refrozen after thawing. Protein concentration of the 
isolated membranes was determined by the Bio-Rad method 
(Bradford, 1976). Typically, isolated axolemma fractions 
were resuspended at 2-10 mg/ml protein concentration. 
Axolemma from bovine white matter was isolated as 
described by Detskey et al. (1988). Membranes were stored 
at -10° C until used. 
thawing. 
Membranes were not refrozen after 
--Measurement of Proliferative Response: 
The ( 3H]-thymidine incorporation assay was carried out 
as described by Yoshino et al. ( 1984) . After the Schwann 
cell cultures were treated with anti-Thy 1.1, (see above), 
the cells were plated in 96-well dishes at a density of 
8,000 cells per well in 100 µl of HF. Membranes or 
chemical pretreatments were added to the Schwann cells 48 
hr later to bring the total volume in each well to 100 µl. 
One day later 0.3 f,Ci of ( 3HJ-thymidine (15-16 Ci/mmole, 
NEN Research Products) in 25 µl of HF was added to each 
well. 
The cells were harvested 48 hr after addition of the 
label. Media containing ( 3H]-thymidine was removed from 
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the cells, and cells dissociated from the plate using 0.05% 
trypsin and o. 04 % EDTA. Cells were collected on Skatron 
filtermats using a Titertek cell harvester. Two filters 
stacked on top of each other were used/per 96 well plate. 
Each set of 12 wells to be harvested was prewetted with 7 
seconds of washing followed by 7 seconds of aspiration. 
Wash media for the cell harvester consisted of 1 part 
distilled water and 1 part isotonic saline. After the 
first set of filters for twelve wells was wetted, the cell 
harvester head was moved to the first twelve wells to be 
harvested; cells were transferred to filters by a 7 second 
wash followed by 7 seconds of aspiration. Subsequent wells 
were harvested in a similar manner. Filters were placed in 
5 ml of complete counting cocktail in 5 _ml liquid 
scintillation vials. The radioactivity on the filters was 
determined by use of a Beckman LS 5801 scintillation 
counter, using preset channel #1 (4 minutes/vial). 
--Treatment of the Axolemmal Membrane: 
Mitogenic activities of all treated and untreated 
axolemma prepara_tions were calculated at 4 or more 
concentrations on the linear portion of the dose response 
curve to obtain a specific mitogenic activity, which was 
used to determine units of mitogenicity as well as 
enrichment of mitogenic activity. 
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Alkaline extraction: sodium carbonate/bicarbonate 
buffer (0.5 M, pH 9) was added to 1-2 mg of axolemma 
membrane to make the final solution 0.27 M in buffer. The 
mixture was incubated overnight at 4° c while stirring 
using a magnetic stir bar and subsequently centrifuged at 
82,500 x g for 1 hr. The supernatant was removed from the 
tube and the pellet was resuspended in isotonic saline 
(0.9%) as a wash step to remove residual pH 9 buffer. The 
membrane was centrifuged as above, and supernatant 
discarded. The washed membrane pellet was resuspended in 
isotonic saline to a volume identical to the starting 
membrane volume. Membranes were stored at -10 ° c until 
used. Once thawed, membranes were not refrozen. pH 9 
supernatants of axolemma were washed with isotonic saline 
using Anticon Centricon-10 microconcentrators. The pH 9 
extract along with isotonic saline was centrifuged in the 
microconcentrators at 3000 x g for 30 min. at 4° c. 
Material retained above the filter (>10 kDa) was mixed 
with isotonic saline and centrifuged as above; this process 
was repeated 2 more times. Washed pH 9 extract was stored 
at 4o C and was not frozen. Typical protein concentration 
of the pH 9 extract was 1-5 mg/ml. 
Heparitinase treatment: One unit of heparitinase 
(Sigma, St. Louis, MO; 0.1 units/ µl) was added to axolemma 
(2-6 mg/ml) for 4 hr. All incubations were carried out in 
a final volume of 400 µl at 37° C while shaking, and 
incubations were terminated by centrifugation at 135,000 x 
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g in a Beckman airfuge for 1 hr to obtain a soluble 
fraction and an insoluble pellet. 
Heparin treatment: Heparin (Sigma, from porcine 
intestinal mucosa) was added to axolemma for the times and 
concentrations indicated. Heparin was dissolved in sterile 
water and added in a volume of 100 µl All incubations 
were carried out at 37° c in a volume of 400 µl while 
shaking. Incubations were terminated by centrifugation at 
135,000 x g for 1 hr as above to obtain a soluble fraction 
and an insoluble pellet. Heparin-solubilized mitogenic 
extracts were heat inactivated by boiling at 100° c for 10 
min. 
--Gel Electrophoresis: 
Sodium dodecyl sulfate -polyacrylamide gel 
electrophoresis (SOS-PAGE) was carried out in 10% 
acrylamide gel by the method of Laemmli (1970) or in 11-23% 
Amersham precast gradient gels as indicated. Samples were 
loaded onto gels in volumes of 10-90 µl. Ten percent gels 
were run at constant current using 15 milliamps for 1. 5 
hours followed by 40 milliamps for an additional 1.5 hours 
or until tracking dye reached the gel front. Gradient gels 
were run at constant current using 15 milliamps for 20 
minutes followed by 40 milliamps for 4 hours or until 
tracking dye reached the gel front. Proteins in the gel 
were visualized with a silver stain kit (Bio-Rad). 
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--Production of Monoclonal Antibodies: 
using 
Antibody-producing murine 
the methods of Taggart 
hybridomas were developed 
and Samloff (1983) and 
monoclonals were isolated using limiting dilutions. One 
male RBF/Dn mouse was injected intraperitoneally (IP) with 
60 ,-g (300 µl) of mitogenic soluble heparin extract 
emulsified in a 1: 1 ratio ( 300 µl) 
adjuvant 
injected 
(CFA). 
(IP) with 
Nine days later 
another 2 o ,-g 
of complete Freund' s 
the same mouse was 
(100 µl) of heparin 
extract in CFA. After another 9 days the same mouse was 
injected (IP) with 28 ,-g of heparin extract (140 µl) in 
incomplete Freund's adjuvant (IFA). 
mouse was injected (IP) with 30 ,-g 
Twelve days later the 
(160 µl) of heparin 
extract in IFA. Twenty days later the mouse was injected 
intravenously (IV) with 20 ,-g (100 µ1) of heparin extract 
in isotonic saline. 
Three days later the immunized mouse was anesthetized 
by ethyl ether and serum was collected from the mouse by 
tail bleed. The spleen was removed from the mouse and 
placed in a petri dish containing wash media: (RPMI-1640). 
Excess fat was removed from the spleen, and the spleen 
tissue was forced through a stainless steel wire mesh 
screen with a 5 ml plastic syringe plunger. Dissociated 
tissue was collected in a 100 mm plastic petri dish 
containing 5 ml of wash media. Tissue was transferred to a 
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50 ml centrifuge tube; the petri dish was washed with media 
to collect residual spleen cells, bringing the total volume 
of the centrifuge tube to 35 ml. Cells were centrifuged 
for 10 min at 400 x g. 
pelleted cells. Five 
Supernatant was removed from the 
ml of Gey' s solution ( Shook and 
Schwartz, 1986) 
blood cells. 
was added to spleen cells to lyse red 
The cells were then mixed via vortexing. 
Cells were placed on ice for 5 min, and then centrifuged 
as above for 5 min. Spleen cells were washed three times 
with wash media by centrifugation as above. The number of 
viable spleen cells obtained was determined by trypan blue 
dye exclusion using a hemacytometer. 
Spleen cells were combined with FOX-NY myeloma cells 
in a 2:1 ratio as described (Shook and Schwartz, 1986). 
Spleen cells and myeloma cells were fused using 
polyethylene glycol at 37° C. Fused cells were plated onto 
96-well plates in 200 µl of (adenine, aminopterin, 
thymidine) (AAT)-selection media (Taggart and Samloff, 
1983) at a density of 2. 6 x 105 cells/well. Cells were 
maintained in 7% co2 at 37
° c for 10-14 days until screened 
as described using enzyme linked immunosorbent assay 
(ELISA) techniques. 
A second male RBF/Dn mouse was injected (IP) with 120 
i-g (600 µl) of mitogenic soluble heparin extract emulsified 
in complete Freund's adjuvant as above. Seven months later 
the same mouse was injected (IP) with 50 i-g (250 µl) of 
heparin extract in complete Freund's. Ten days after this, 
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the mouse was injected (IV) with 20 1-9' (100 µl) of heparin 
extract in isotonic saline. Three days later immune serum 
was collected from the mouse and the spleen cells were 
fused with myeloma cells as described above. 
--Enzyme Linked Immunosorbent Assay: 
Enzyme linked immunosorbent assay (ELISA) was carried 
out using the general techniques outlined by Shook and 
Schwartz (1986) with modifications. The antigen was 
diluted to the indicated concentration in phosphate 
buffered saline (PBS) and delivered in 100 µl/well of a 96-
well microelisa plate. The microelisa plate was incubated 
at 4 ° overnight. The following day, contents of the plate 
were emptied by inversion; as much of the liquid was 
removed as possible by shaking the plate over paper towels. 
Primary antibody samples were added in the amount of 100 
µl/well. When dilution of the primary antibody was 
necessary, dilution was carried out using 1% bovine serum 
albumin (BSA) in PBS. After primary antibody was delivered 
to the wells, all wells were covered with 100 µl of 5% milk 
in PBS as a block against non-specific binding. Primary 
antibody remained on the plate for 1-2 hours. Antibody was 
removed by submerging the ELISA plate in a beaker of 
running tap water and then inverting the plate to remove 
liquid. This process was repeated approximately 5 times. 
Secondary antibody (goat anti-mouse, Boeringer-Mannheim) 
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conjugated to horseradish peroxidase was diluted 1:600 with 
1% BSA in PBS and delivered in the amount of 100 µl to each 
well of the ELISA plate. To inhibit non-specific binding, 
100 µl of 5% milk in PBS was added to each well as above. 
Secondary antibody remained on the plate for 1-2 hours. 
Antibody was washed from the plate using running tap water 
as described above. The extent of antibody reaction was 
then determined using the peroxidase substrate. Peroxidase 
substrate consisted of 1 part 40 mM ABTS (2,2' azino-di-3-
ethylbenzothiazoline sulfonic acid) in distilled water, 19 
parts citrate buffer (0 .1 M citric acid + o .1 M sodium 
citrate) at pH 4.0, and 20 parts 0.3% H2o2. The peroxidase 
substrate was .delivered in the amount of 100 µl/well and 
allowed to react for 15-30 min. Optical density was then 
read at 405 nm using a Titertek Multiskan 
spectrophotometer. 
--Pretreatment of Axolemma and Schwann Cells with 1A5-2G3: 
1A5-2G3 hybridomas were grown in a defined medium 
(Chen and Devries, 1989) consisting of the following 
components: Dulbecco's modified Eagle medium and Ham's F-
12 1: 1 with sodium bicarbonate, 1. 2 g/L, and 15 mM HEPES 
buffer (pH 7. 2) ; insulin ( 5 i-g/ml) ; human transferrin ( 50 
i-g/ml); triiodothyronine (15 nM); sodium selinate (30 nM); 
hydrocortisone (20 i-g/ml); dibutyryl cyclic AMP (1 µ'1); 
sodium pyruvate (110 i-g/ml); and bovine serum albumin (1 
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mg/ml). Supernatants were collected and stored at -10° C. 
Dilutions of concentrated antibody were combined with 
axolemma and shaken using a Bellco shaker at 4° c for at 
least 1 hour. Antibody-axolemma mixture was added to · 
Schwann cells and proliferative response measured as 
described above. For pretreatments with nonspecific IgM, 
identical methods were used with Sigma IgM K (TEPC 183). 
IgM levels in both the 1A5-2G3 supernatants and Sigma IgM 
were compared using ELISA techniques so that the same 
amount of specific and non-specific IgM was used. In 
experiments where Schwann cells were pretreated with 
antibody, cells were exposed to antibody at the indicated 
concentration for 24 hours in a 10 % CO2 incubator at 37.
o 
C. The media was subsequently removed from the cells and 
mitogens were added as described above. 
--Antibody Affinity Column: 
Monoclonal antibody 1A5-2G3 or Sigma IgM (TEPC 183) 
was conjugated to Pharmacia activated CH-Sepharose 4B as 
recommended by the product instructions. The Sepharose 
powder was suspended in 1 mM HCL and was washed for 15 min. 
with 1 mM HCL on a sintered glass filter; 1 gram of 
Sepharose powder produced approximately 3 ml of swollen 
gel. Approximately 200 ml of 1 mM HCL/g of Sepharose 
powder was used as a wash. Monoclonal antibody was 
equilibrated in coupling buffer (NaHC03, O. 1 M, pH 8. O, 
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containing NaCl, 0.5 M, 5 ml per gram of Sepharose powder) 
using Centricon 30 microconcentrators. The coupling buffer 
was exchanged with the media of the IgM supernatants by 
mixing the antibody with coupling buffer in the Centricon 
tubes and centrifuging the mixture at 3000 x g for 30 min. 
at 4° c. The material retained above the filter (>30 kDa) 
was mixed with coupling buffer and centrifuged as above. 
This · process was carried out a third and final time; 
material retained above the filter was mixed with coupling 
buffer up to 5 ml and added to the Sepharose gel in a 
stoppered vessel. This mixture was gently shaken at 4o c 
overnight. Excess monoclonal antibody was washed away with 
coupling buffer and the remaining active groups on the 
sepharose gel were blocked with 
Tris(hydroxymethyl)aminomethane (Tris) -HCl buffer (0.1 M, 
pH 8) for 1 hour. The product was then washed with three 
cycles of alternating pH. Each cycle consisted of a wash 
(15 ml of each buffer/wash) at pH 4 (0.1 M acetate buffer 
containing 0.5 M NaCl) followed by a wash at pH 8 (0.1 M 
Tris buffer containing 0.5 M NaCl). The product was stored 
at 4o c in 0.1 M Tris buffer containing 0.5 M NaCl. 
An affinity column was prepared as described above 
using monoclonal antibody 1A5-2G3. The Sepharose gel was 
packed into a 1 ml syringe with glass wool packed at the 
tip to prevent leakage of the gel. All samples were loaded 
in 250 µl volumes, and after allowing the meniscus of the 
liquid sample to enter completely into the sepharose gel, 
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the column was placed in a glass test tube and centrifuged 
at setting 1 on an IEC clinical centrifuge for 1 min at 
room temperature. After each centrifugation, samples 
eluted from the column were collected and saved for further 
analysis. Samples which differed by more than 1 pH unit 
(as determined by litmus paper) from the wash buffer (0.1 M 
Tris, 0.5 M NaCl, pH 8) were immediately adjusted to pH 6-8 
with solid Tris. 
Alternatively, resin coupled with 1A5-2G3, or Sigma 
IgM (TEPC 183) as a non-specific source, was shaken with 
mitogenic heparin extract overnight at 4 ° C in a  microfuge 
tube. The same amount of 1A5-2G3 and Sigma IgM was 
interacted with the resin as determined by ELISA 
techniques. After the heparin extract was shaken with the 
coupled resins, the microfuge tubes were centrifuged at 
approximately 200 x g for 1 min at room temperature and 
supernatants removed. Resin was then washed with buffer as 
above via vortexing. Supernatants were collected and 
sterile filtered for further analysis. 
For both columns and resins in microfuge tubes, 
proteins bound to the resins were eluted using urea. Urea 
was made at 6 M concentration and added to resins at full 
molar strength or in stepwise gradient fashion as 
indicated. Urea was added to resins for the same time and 
in the same fashion as described for samples and washes. 
Eluted fractions using urea were sterile filtered and saved 
for further analysis. 
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Dialysis of urea fractions was carried out using ISCO 
dialysis cups and 3500 MW cutoff Spectra-par dialysis 
tubing. Urea fractions were dialys·ed with distilled water 
at 4° C overnight with frequent changes· of the water. 
--concentration of IqM Monoclonal Antibodies: 
IgM monoclonal antibodies were concentrated by 
filtration using Amicon XM300 ultrafilters. The IgM 
supernatant of hybridomas grown in defined media (see 
above) was collected and centrifuged at 1,000 rpm to remove 
cellular debris. After centrifugation, hybridoma 
supernatant was removed from the cell pellet and stored in 
sterile tubes at -70° c. To concentrate the IgM antibody, 
the hybridoma · supernatant was thawed and then placed in a 
50 ml amicon concentrator. Using XM300 ultrafilters, the 
hybridoma supernatant was then concentrated using nitrogen 
gas at a pressure of 55 psi. Concentrations were carried 
out at 4° C. Use of XM300 ultrafilters allowed the IgM 
antibody (MW of approximately 900 kDa) to be concentrated, 
while all other proteins in the defined media passed 
through the filter. After concentration the IgM antibody 
was then sterile filtered by passage through a o. 2 micron 
filter. 
Final 
Sterile concentrated antibody was stored at 4° c. 
protein concentrations after filtration were 
approximately 30 mg/ml. 
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--Filtration of Heparin Extract 
Mitogenic heparin extract was centrifuged in a 
Centricon 30 microconcentrator at 3000 x g for 30 min. at 
4°. The material retained above the filter (>30 kDa) was 
saved in a sterile tube for further analysis. The material 
passing through the filter (<30 kDa) was centrifuged in a 
Centricon 10 microconcentrator as above. The material 
retained above the filter (<30 >10 kDa) and passing through 
the filter (<10 kDa) was saved as above. 
RESULTS 
--Preliminary Studies: 
Previous results in our laboratory had demonstrated 
that axolemma could be fluorescently · labelled with 
fluoresein isothiocyanate (FITC) or tetramethyl rhodamine 
isothiocyanate (TRITC) as a means for studying the physical 
interaction between Schwann cell and axon (Meador-Woodruff 
et al., 1985). We extended these studies by developing a 
fluorescent binding assay which measured the extent of 
binding of fluorescently labelled axolemma to Schwann cells 
under different conditions. 
--!21! � Treatment of Axolemmal Membrane: 
As we further investigated the properties of FITC 
labelled axolemma, we realized that to be a valid probe the 
membrane should not be significantly altered during the 
labelling process: otherwise, the labelled membrane would 
not be useful in reporting the effect of normal axolemma 
added to cultured Schwann cells. A control experiment 
which we carried out led to a dramatic and surprising 
result. We treated axolemma membrane with sodium 
carbonate/bicarbonate buffer ( O. 27 M pH 9) as we would 
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during the FITC labelling procedure (see above). However, 
when this procedure was carried out in the absence of 
fluor, 50% of the protein was removed into the supernatant 
during the centrifugation step. The supernatant could- not 
be directly tested for mitogenicity to Schwann cells 
because of the high pH and molar strength of the buffer 
which was toxic to Schwann cells. What was surprising was 
that the membrane pellet contained 50% of the starting 
protein, and yet contained 
Thus, 
95% of the mitogenicity of the 
the pH 9 treated axolemma was starting material. 
enriched 2-fold 
axolemma. 
in mitogenicity compared to untreated 
Figure 1 shows a dose response curve of pH 9 treated 
and untreated axolemma added to Schwann cells, measuring 
the mi togenic effect of these membranes. At all protein 
concentrations of membrane tested, pH 9 treated axolemma 
was significantly more mitogenic than untreated axolemma. 
Thus, while 50% of the starting axolemmal protein was 
extracted by pH 9 buffer treatment, little or none of this 
protein appeared to be mitogenic: 95% of the starting 
mitogenicity remained with the pellet. This result was 
indirect evidence that the axolemmal mitogen for Schwann 
cells was still membrane bound after pH 9 extraction; in 
this respect the mitogen had been characterized as base­
stable. 
Because the pH 9 extract of axolemma was toxic to 
Schwann cells when added to them directly, the above 
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Figure 1. Enrichment of axolemmal mitogen after alkaline 
treatment. Axalemma was treated with 0.27 M pH 9 buffer as 
described in Materials and Methods. The pH-9 treated 
(triangles) or untreated (filled circles) axalemma was 
added to Schwann cells at the indicated concentrations of 
protein. Control cells (open circles) received media only. 
Each point represents five or more determinations and 
standard deviations are indicated. Where no error bars 
appear, the standard deviation is less than the range 
occupied by the symbol. 
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evidence of 95% of the mitogenic activity remaining with 
the axolemmal pellet did not exclude the possibility that 
we had removed some type of inhibitor, and that the 
alkaline extract of axolemma was also mitogenic. To test 
this possibility we washed the extract with isotonic saline 
4 times using a Centricon 10,000 mw cutoff tube as 
described in Materials and Methods. After protein was 
determined for the pH 9 extract, we tested the extract and 
untreated axolemma for mitogenicity to Schwann cells. 
Figure 2 shows that compared to untreated axolemma, the pH 
9 extract contains low levels of mitogenic activity. This 
further supports the idea that the majority of mitogenic 
activity remains associated with the axolemmal membrane 
after pH 9 extraction, and that little or no mitogen is 
extracted by pH 9 treatment. 
To test whether axolemmal proteins were dissociating 
from the membrane non-specifically, we treated axolemma 
with isotonic saline (0.9 %) under the same conditions as 
the pH 9 extraction. Figure 3 shows that axolemma treated 
with isotonic saline was not significantly altered in its 
mitogenicity towards Schwann cells compared to the 
untreated starting axolemma. Both untreated axolemma and 
axolemma treated with isotonic saline were significantly 
mitogenic at the concentrations tested. 
In an attempt to determine if more nonmitogenic 
material could be removed from the axolemma by pH 9 
extraction, we treated axolemma with sodium 
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Figure 2. Mitogenic activity of pH 9 extract of axolemma, 
and untreated axolemrna. Axolemrna was treated with 0.27 M 
pH 9 buffer as indicated in Materials and Methods. pH 9 
extract of axolemrna (open triangles) was washed 4 times 
with isotonic saline using a Centricon 10,000 mw cutoff 
tube as described in Materials and Methods and tested for 
mitogenicity to Schwann cells at the indicated protein 
concentrations; filled circles indicate rnitogenic effect of 
untreated axolemrna; open circles indicate the effect of hf 
alone on Schwann cells. Each point represents 5 or more 
determinations and standard deviations are indicated. 
Where no error bars appear, standard deviation is less than 
the range occupied by the symbol. 
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Figure 3. Treatment of axolemma with isotonic saline. 
Axolemma was treated under identical conditions as pH 9-
treated axolemma, but using isotonic saline instead of pH 9 
buffer. Axolemma treated with isotonic saline (filled 
bars) or untreated axolemma (open bars) was added to 
Schwann cells at the indicated protein concentrations. 
Control cells (hatched bars) received media only. Each bar 
represents five or more determinations and standard 
deviations are indicated. 
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carbonate\bicarbonate buffer (pH 9) at 0.4 M strength. 
This treatment was carried out in the same manner as that 
using 0.27 M buffer. However, when treated with 0.4 M pH 9 
buffer, the axolemma pellet obtained was not significantly 
mitogenic at any of the protein concentrations tested (fig. 
4). In addition, no detectable mitogenic activity was 
observed in the extracted supernatant. This result 
indicated that the axolemmal mitogen was being inactivated 
using pH 9 buffer at 0.4 M strength, whereas at 0.27 M 
strength the mitogenic activity remained associated with 
the membrane to the extent of 95% activity. 
The ability for the mitogenicity of axolemma to 
Schwann cells to remain associated with the membranous 
pellet after O. 27 M pH. 9 extraction indicated that the 
molecule responsible for mitogenicity might be basic in 
character: while other proteins were extracted from the 
starting axolemma (50%), those responsible for mitogenicity 
were not. The pH 9 extraction procedure was specific in 
that using identical conditions as a pH 9 extraction, 
neither detectable protein nor mi togenici ty was extracted 
from starting axolemma by treatment with isotonic saline. 
In an attempt to determine if a greater percentage of 
nonmi togenic protein could be extracted from axolemma by 
higher molar strength pH 9 buffer (0.4 M), it was 
determined that O. 27 M strength was permissive for 
extraction without inactivating the mitogenic activity. 
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Figure 4. Treatment of axolemma with o. 4 M pH 9 buffer. 
Axolemma was treated with 0.4 M pH 9 buffer with all other 
conditions identical to those used for treating axolemma 
with 0.27 M pH 9 buffer. Axolemma treated with 0.4 M pH 9 
buffer (hatched bars) or untreated axolemma (filled bars) 
was added to Schwann cells at the concentrations of protein 
indicated. Control cells (open bars) received media only. 
Each bar represents five or more determinations, and 
standard deviations are indicated. 
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--Heparitinase Treatment of Axolemmal Membrane: 
The results of 0.27 M pH 9 extraction of axolemma 
indicated that the mitogenicity was not dissociated from 
the membrane by this treatment, and thus, that the 
mitogenic factors in axolemma might be basic in nature 
themselves, or highly positively charged. The mitogen 
might thus be associated with negatively charged groups on 
the axonal surface. This idea had added significance in 
light of experimental results by Ratner et al. (1985), 
which indicated that interfering with proteoglycan 
synthesis of neurons or treatment of neuritic membranes 
with heparitinase to break down the heparan sulfate 
glycosaminoglycans, significantly depleted the mitogenicity 
of these membranes to Schwann cells. The negatively 
charged heparan sulfate proteoglycans thus seemed important 
to the mitogenic activity of axons to Schwann cells. 
Heparitinase is an enzyme which cleaves the glycosidic 
bonds of sulfated glycosaminoglycans. We postulated that 
if heparitinase depleted the mitogenicity of neurite 
membranes to Schwann cells (Ratner et al., 1985), it might 
do so by releasing a positively charged mitogen bound to 
the sulfated heparan sulfate proteoglycans. Since the pH 9 
extraction evidence from our work indicated that the 
axolemmal mitogen might be positively charged, we 
investigated the effect of heparitinase on axolemma. 
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Figure 5 shows that when axolemma is treated with 
heparitinase, a soluble extract can be obtained which is 
mitogenic to Schwann cells. 
breaking the glycosidic 
This result 
bonds 
indicated that 
of sulfated 
glycosaminoglycans released mitogenic activity from the 
axolemmal membrane. Such a mechanism may have been 
responsible for depleting the mitogenicity of neuritic 
membranes reported by Ratner et al. (1985). In any event, 
it seemed that sulfated proteoglycans were involved in the 
mitogenicity of axolemmal membranes, and this result 
further supported our idea that the axolemmal mitogen was 
positively charged. 
Figure 5 shows that as the dose of heparitinase 
extract is increased (and thus the amount of heparitinase, 
which is soluble), Schwann cell proliferation decreases. 
The heparitinase control contains the amount of 
heparitinase found in the highest dose of heparitinase 
soluble extract (assuming that all heparitinase added 
remains soluble). Compared with cells which received 
medium only, we can see that hepari tinase alone exerts a 
slight inhibitory effect on Schwann cell proliferation. 
In addition to the inhibitory effects which 
heparitinase has on Schwann cell proliferation, figure 5 
shows that the axolemmal membrane pellet which has been 
treated with heparitinase is still very mitogenic. In 
fact, only at the lowest doses tested is the heparitinase 
soluble extract as mitogenic as the recovered (treated) 
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Figure 5. Solubilization of axolenunal mitogen via 
heparitinase treatment. Heparitinase-treated axolenuna was 
prepared as described in Material and Methods. The soluble 
extract (open triangles) or recovered (heparitinase­
treated) pellet (closed triangles) was added to Schwann 
cells at the indicated concentrations of protein. Control 
cells (open circles) received media only. The heparitinase 
control (filled circles) represents cells treated with 
heparitinase at the same concentration as would be found in 
the highest dose of soluble extract. Each point represents 
five or more determinations, and standard deviations are 
indicated. Where no error bars appear, the standard 
deviation is less than the range occupied by the symbol. 
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pellet. Therefore, heparitinase is not preferentially 
solubilizing the axolemmal mitogen since the heparitinase 
extract does not have a higher specific mitogenic activity 
than the pellet. 
--Heparin Treatment of Axolemmal Membrane: 
The results of pH 9 extraction of axolemma supported 
the idea that the axolemmal mitogen is positively charged. 
Results from heparitinase treatment of axolemma indicated 
that sulfated glycosaminoglycans (possibly in the form of 
heparan sulfate proteoglycans) were also important to the 
mi togenici ty of axolemma. We postulated from these two 
pieces of evidence that it might be possible to dissociate 
the axolemmal mitogen from the membrane surface using a 
heparan sulfate analogue such as heparin. 
Kraemer (1977) had shown that heparin releases heparan 
sulfate from the surface of cells, and the work of Kjellen 
et al. (1980) indicated that the heparan sulfate 
proteoglycans on cell surfaces could be found in both 
heparin displaceable and non-displaceable forms. We 
reasoned that the positively charged nature of the 
axolemmal mitogen would 
negative charge of the 
(which is negatively 
allow it to associate with the 
sulfated proteoglycans. Heparin 
charged) might dissociate the 
axolemmal mitogen from the membrane surface by dissociating 
the mitogen from the sulfated proteoglycans, or by 
displacing the proteoglycan-mitogen complex 
axolemmal membrane s�rface. 
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from the 
Figure 6 shows that when we treated axolemmal membrane 
with a 1 mg/ml solution of heparin, mitogenic activity was 
preferentially solubilized. At all doses tested, the 
heparin soluble extract was more mitogenic than the 
recovered (treated) pellet. In addition, at the highest 
doses of heparin extract tested (assuming that all heparin 
added remained soluble) heparin alone had no effect on 
Schwann cell proliferation. 
When compared to the starting axolemma, the heparin 
treated axolemma pellet was decreased in mitogenicity. As 
shown in figure 7, the specific mitogenic activity of the 
heparin extract is increased approximately 6-fold compared 
to starting material. The lower specific mitogenic 
activity of the heparin treated pellet indicates that we 
have not revealed any mitogenic activity. Thus, we have 
preferentially partitioned the mitogenic activity into the 
soluble extract: the extract has a higher specific 
mitogenic activity at the expense of the recovered (heparin 
treated) pellet. 
To investigate whether more concentrated levels of 
heparin could extract greater amounts of mitogenicity from 
the axolemmal membrane, we treated axolemma with a 2 mg/ml 
solution of heparin. Although 70% more protein was 
solubilized using the more concentrated heparin treatment 
(Table 4), very little mitogenicity was extracted (see 
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Figure 6. Solubilization of axolenunal mitogen via heparin 
displacement. Heparin-treated axolenuna was prepared as 
described in Materials and Methods. The soluble extract 
(open triangles) or the recovered (heparin-treated) pellet 
(filled triangles) was added to Schwann cells at the 
indicated protein concentrations. Control cells (filled 
circles) received media only or heparin at the same 
concentration as would be found at the highest dose of 
soluble extract (50 �/ml of heparin). Cells treated with 
heparin at 50 �/ml did not differ in mitotic response from 
those treated with media only. Each point represents five 
or more determinations and standard deviations are 
indicated. 
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Figure 7. Specific mitogenic activity of heparin­
solubilized extract, heparin-treated axolemma, and 
untreated axolemma. The mitogenic activity of heparin­
solubilized extract of axolemma (open circles), untreated 
axolemma (open triangles), and heparin-treated axolemma 
pellet (closed circles) was determined at the protein 
concentrations indicated. Five or more determinations were 
obtained for each point; determinations were averaged and 
the background level of proliferation (indicated by cells 
receiving media only) subtracted from these averages. The 
proliferative response in the presence of mitogen minus the 
background response was divided by the amount of mitogen 
used to obtain the specific mitogenic activity. 
60 
Table 1). One possible explanation for the low levels of 
mitogenicity in the 2 mg/ml heparin extract was the toxic 
effect of heparin itself. At the highest dose of heparin 
extract tested (assuming all heparin added remains soluble) 
heparin does inhibit proliferation of Schwann cells 
slightly: the heparin control showed approximately half 
the level of proliferation as cells receiving- HF only. 
However, as Table 1 demonstrates, even diluting the heparin 
extract (and thus the amount of heparin) did not result in 
any increase in mitogenic activity. Thus the 2 mg/ml 
heparin extract was not inhibiting Schwann cell 
proliferation in the same manner as observed in the 
heparitinase experiment (where decreasing doses were more 
mitogenic). 
It seems that the effect that heparin exerts on 
extracting axolemmal protein is a dynamic one. While a 
greater percentage of protein is extracted using 2 mg/ml of 
heparin compared to 1 mg/ml, the population of molecules 
extracted also appears different (see also figure 10). The 
toxic effect of heparin at higher concentrations does not 
appear to fully explain why less mitogenic activity is 
recovered in the heparin extract using 2 mg/ml treatment. 
As shown in table 1, when we account for the concentration 
of heparin in 
( assuming that 
protein doses 
the 1 mg/ml and 2 mg/ml heparin extracts 
all heparin added remains soluble) , some 
for the two different treatments are 
TABIE 1: MI'IOGENIC rorENTIAL OF HEPARIN �crsa 
1 ng/ml 2 ng/ml 
PROTEIN IX>SE HEPARIN EXI'RACTION HEPARIN EXI'RACTION 
0 + HF 1451 ± 196 (O)b 481 ± 137 (0) 
0 + HEPARIN 1164 ± 237 (40) 283 ± 49 (53) 
9.5 µg/ml N. o.c 464 ± 42 (53) 
7.1 µg/ml N. D. 447 ± 69 (40) 
6.2 µg/ml 2656 ± 399 (40) N. D. 
4. 7 µg/ml N. D. 411 ± 67 (26) 
3.1 µg/ml 1884 ± 245 (20) N. D. 
ar.titogenic potential of heparin extracts using 1 ng/ml or 2 
ng/ml of heparin are represented at the indicated protein 
concentrations as dpm of (3H]thymidine inco:rporated by Schwarm 
cells as detennined by cell hal:vester techniques. Each data 
point represents 5 or more detenninations and standard 
deviations are indicated. 
bpigures in parenthesis indicate the amount of heparin (µg/ml) 
included in the given protein dose, assuming that all heparin 
used in the extraction remained soluble. 
�- D. = not detennined. 
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comparable, and yet the protein extracted by the 2 mg/ml 
treatment is only marginally mitogenic. 
The work of Devries et al. ( 1982) showed that 
Schwann cells cultured from rat sciatic nerve could be 
stimulated to proliferate by both rat and bovine CNS 
axolemma membranes. To investigate whether the mi togenic 
activity of bovine CNS axolemma membranes could be 
extracted with heparin, bovine white matter was treated 
with a 0.5 mg/ml concentration of heparin for 60 min., and 
the soluble extract and extracted pellet were tested for 
mi togenici ty toward Scl:iwann cells. As shown in table 2, 
although the starting material and extracted pellet were 
mitogenic, the heparin extracted protein from bovine CNS 
white matter was not. Under the same conditions, rat CNS 
axolemma showed mitogenic activity in the heparin soluble 
extract at protein doses comparable to those extracted from 
bovine sources. 
Although the heparin extract from bovine white matter 
was not mitogenic (see table 2), the heparin appeared to be 
extracting more protein with time. As in the work of 
Kraemer (1977) we too saw a rapid increase in the protein 
solubilized by heparin after only 5 min. We also observed 
a gradual increase in the amount of protein solubilized 
after 30 minutes treatment with heparin (fig. 8). 
Table 3 summarizes the mitogenicity of similar doses 
of rat axolemma heparin extracts obtained under varying 
conditions, as well as the amount of protein solubilized by 
TABIB 2: MI'I'CGENIC ACI'IVITIES OF RAT AND OOVINE AXOLEMMAL 
HEPARIN IDITRACI'S, TREATED PELIEIS, AND STARl'ING AXOLEMMAa 
PROI'EJN OOSE 
0 + HF 
8.4 µ.g/ml 
6.8 µ.g/ml 
5.6 µ.g/ml 
5.1 µ.g/ml 
51.5 µ.g/ml 
42.3 µ.g/ml 
75.2 µ.g/ml 
65.1 µ.g/ml 
RAT AXOIBMMA 
1.066 ± 0.337 
0.953 ± 0.377 
HEPARIN IDITRACI'S: 
3.906 ± 0.716 
N. D. 
2.893 ± 0.645 
N. D. 
TREATED PELIEIS: 
14.546 ± 1.599 
N. D. 
STARl'ING MEMBRANE: 
25.124 ± 2.773 
N. D. 
OOVINE AXOLEMMA 
0.962 ± 0.230 
0.780 ± 0.194 
N. D.c 
0.994 ± 0.248 
N. D. 
1.333 ± 0.408 
N. D. 
12.354 ± 0.900 
N. D. 
22.803 ± 5.581 
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aRat or bovine axolemma was treated with 0.5 rrg/ml of heparin for 
60 minutes as indicated in Materials and Methods. The mi toqenic 
activities for each protein dose are expressed as dprn x 10-3 of 
(3H]thymidine uptake by Sc.hwann cells as determined by cell 
harvester. Each data point represents 5 or more determinations 
and standard deviations are indicated. 
bireparin control contained 20 µ.g/ml of heparin. 
Gt.. D. = not determined. 
64 
10 
z 9 0-0 
w z 8 
/
0
�
0 
BOVINE 
f-- ix 
0 <( XOLEMMA a::: Q._ 7 
Q._ w 
0 I 6 w >- o--o a::: m 5 w 
I 
> 0 
0 w 4 
<.) 
f--
w (_) a::: <( 3 a::: 
LL f-- 2 0 X w 
� 
0 
10 30 50 360 
TIME (MINUTES) TREATED WITH HEPARIN 
Figure 8. Percent of bovine axolemma protein extracted 
with time. Bovine axolemma was extracted with 0.5 mg/ml of 
heparin as indicated in Materials and Methods for the 
amounts of time indicated. The percent of recovered 
protein extracted by heparin was determined using the Bio­
Rad protein determination. 
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'IBE1l'.IMENI' 1: 
_0.5nglml� 
fat" 60 m:inrt:es 
% OF REX:o.1ERED IroIEIN 
ElcrWCIED BY HEPARIN 
cells treat.Erl with o. 56 µg of extract: 
HEPARIN <XNIKlL: 0.953 ± 0.377 
HEPARIN EX!RllCI': 2.893 ± 0.645 
'IBE1l'.IMENI' 2 : 
lng/ml� 
for 180 m:inrt:es 
6.8% OF IroIEIN 
EXIRI\CIED BY HEffiRIN 
cells treat.Erl with 0.62 µg of extract 
HEPARIN a::NIIDL: 1.164 ± 0.237 
HEE¥IRIN EX!RllCI': 2.656 ± 0.339 
'IBE1l'.IMENI' 3 : 
1 nqtml h;p3rin 
fat" 360 m:inrt:es 
7.6 % OF IRJIEIN 
EXIFACim BY HEPARIN 
cells t:.re:rt:.erl with O. 55 µg of extract: 
HEPARIN a::NIIDL: 1.800 ± 0.530 
HEPARIN EX!RllCI': 2.2U ± 0.335 
'ffiEl\'.IMENI' 4 : 
2 nqtml h;p3rin 
for 240 m:inrt:es 
7.3 % OF� 
EXIRACI'ED BY HEPARIN 
cells t:.re:rt:.erl with o. 47 µg of extract 
HEPARIN a::NIR)L: 0.283 ± 0.049 
HEPARIN ElcrRllCI': 0.411 ± 0.067 
11.9 % OF :ffiJI'EIN 
EXIRACI'ED BY HEPARIN 
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these different treatments. We found that after 60 min. 
with either o.s mg/ml or 1 mg/ml concentration of heparin, 
mitogenic activity was extracted from axolemma. However, 
if heparin concentration or treatment time was increased 
too much, little mitogenic activity was recovered. 
As described by Yoshino et al. (1984), both axolemma 
and myelin-enriched fractions produced a dose-dependent 
uptake of ( 3HJ thymidine into Schwann cells; however, the 
shape of the dose response curves was different for the two 
membranes. As shown in figure 9c, the dose response curve 
of heparin extract from axolemma appears to most closely 
resemble the dose response curve of axolemma (9a). The 
dose response curve for myelin (9b) is hyperbolic in shape 
and shows an immediate rise in [ 3HJthymidine uptake at low 
doses of protein. The dose response curves of heparin 
extract and of axolemma show an initial lag of 
[ 3HJthymidine uptake at low doses of protein, are sigmoidal 
in shape, and continue to rise at protein doses where 
myelin membrane curves have plateaued. 
It should also be noted that due to a higher specific 
mitogenic activity, heparin extract is significantly 
mitogenic at much lower protein doses than the starting 
axolemma membrane; however, when we represent figures 9a 
and 9c as Hill plots (9d and 9e respectively), we see that 
both axolemma and the heparin extract of axolemma have 
similar slopes. Yoshino et al. (1984) found that axolemma 
exhibited a Hill coefficient of approximately 2.0 when 
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Figure 9a. Mitogenic response of Schwann cells to 
axolemma. Axolemma ( closed circles) was added to Schwann 
cells at the protein concentrations indicated. Control 
cells (open circles) received media only. Each point 
represents five or more determinations and standard 
deviations are indicated. Where no error bars appear, 
standard deviations are less than the range occupied by the 
symbols. 
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Figure 9b. Mitogenic response of Schwann cells to myelin. 
Myelin (closed circles) was added to Schwann cells at the 
indicated protein concentrations. Control cells (open 
circles) received media only. Each point represents 5 or 
more determinations and standard deviations are indicated. 
Where no error bars appear, standard deviation is less than 
the range occupied by the symbol. 
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Figure 9c. Mitogenic response of Schwann cells to heparin 
extract of axolemma. Heparin extract of axolemma (closed 
circles) was added to Schwann cells at the indicated 
protein concentrations. Control cells (open circles) 
received media only. Each point represents five or more 
determinations and standard deviations are indicated. 
Where no error bars appear, standard deviation is less than 
the range occupied by the symbols. 
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Figure 9d. Hill plot of axolemma mitogenicity to Schwann 
cells. Data from figure 9a was expressed as a Hill plot to 
d1termine the cooperativity of axolemmal stimulation of 
[ H]thymidine uptake by Schwann cells. Maximum stimulation 
of [ 3H J thymidine uptake was chosen as 3 2, 4 9 o dpm. The 
slope (Hill coefficient) of the plot was determined to be 
2.18. 
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Figure 9e. Hill plot of heparin extract mitogenicity to 
Schwann cells. Data from figure 9c was represented as a 
Hill plot to determine the cooperativity of heparin extract 
stimulation of ( 3HJthymidine uptake by Schwann cells. 
Maximum stimulation of ( 3HJthymidine uptake was chosen as 
7115 dpm. The slope (Hill coefficient) of the plot was 
determined to be 1.90. 
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plotted as ability to stimulate [ 3H]thymidine uptake per f.g' 
of axolemma. The Hill coefficients of Figures 9d and 9e 
are both approximately· equal to 2. O, thus showing similar 
cooperativity in the ability to stimulate [ 3H]thymidine 
uptake per f.g' of axolemma or heparin extract protein. 
--Mitogenic Activity Recoveries of Treated and Untreated 
Axolemma: 
Table 4 presents the quantitative protein and 
mitogenic activity recoveries of untreated, pH 9-treated, 
heparitinase-treated, and heparin-treated axolemma. All 
treatments were carried out on at least two different 
axolemma preparations, and all treated membranes were added 
to at least five different sets of Schwann cells. Data 
from different preparations undergoing the same treatment 
(for example, different pH 9 preparations) showed 
variability in the absolute numbers obtained. In addition, 
theoretically similar membrane such as untreated axolemma 
shows variability in mitogenic activity as shown in Table 
4. This variability is due both to the sensitivity of 
different Schwann cell preparations to membrane mitogen, as 
well as the mitogenic potency of different axolemma 
preparations. For example, the mitogenic activities of 
untreated axolemma shown in Table 4 for the heparitinase 
and heparin experiments cannot be compared: different 
Schwann cell preparations were used to obtain the indicated 
TABIE 4: Protein and mitogenic activity recoveries of untreateda 
pH 9-trea.ted, heparitinase-treated, and heparin-trea.ted axolemoa 
Experilnent Fraction u; of mitogenic protein units of mitogenic 
�:;;�b 
(t of mitogenic activity 
untreated 
(=��)c 
(t of untreated 
axol.EIDl8) axolemna.) 
pH 9 untreated 1870 5333 100 997 100 
axolema 
supernat. 860 N. o.d 45.9 N. o.d N. o.d 
pallet 851 12,017 45.5 1022 102 
t rect:N. 91.5 102 
Heprtnse.e untreated 93.5 8760 100 81.9 100 
axolemna 
supernat. 7.02 6380 7.51 4.47 5.46 
pellet 78.0 9280 83.4 72.3 88.3 
t recov. 90.9 93. 7 
Heparin untreated 714 1015 100 72.4 100 
l nq/ml axolemna 
supernat. 45.0 2406 6.30 10.8 14.9 
pellet 544 804 76.2 43. 7 60.4 
t =· 82.5 75.3 
Heparin untreated 1016 1541 100 156 100 
2 IIJ31ml axolema 
supernat. 110 230 10.8 2.5 l.63 
pellet 824 1657 81.l 136 87.l 
t :recolT. 91.9 ea. 7 
a '.!he data presented represents a typical result fran a,a of each of the different 
treatments (pH 9, heparitinase, and heparin); at least two different o,colemua preparations 
were used for each trea.hnent. See results sectia, of text. 
b '.!he specific mitogenic activity was calculated for the linear porticn of dose response 
c=ves as cles=ibed in the text. 
c Tctal units of mitogenic activity were calculated by llUltiplying total u; of protein by 
the speci!ic mitogenic activity. 
d Mitogenic activity of the pH 9 supernatant was not detemined due to the toxicity of 
the pH 9 buffer on Schwann cells. 
8 Axolemna was treated with 1 unit of heparitinase at 37 degrees c for 4 hours. 
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results for different treatments of the axolemma. Despite 
the variability of mitotic response of different Schwann 
cell preparations and variable mitogenic activity of 
different axolemma preparations, given treatments of 
axolemma always showed the same trends for enrichment .of 
mitogenic activity when compared to the untreated axolemma 
used in that experiment. Therefore the data shown in Table 
4 are typical results from one of each of the different 
treatments (pH 9, heparitinase, and heparin). 
When axolemma obtained from adult rat CNS white matter 
(brainstem) was treated with 0.27 M sodium 
carbonate/bicarbonate buffer at pH 9 and then centrifuged, 
a pellet was recovered which represented 50% ± 5% of the 
starting protein and 95% ± 10% of the starting mitogenic 
activity. The supernatant from the pH 9-treated axolemma 
contained approximately 50% of the starting protein; 
although the mitogenicity of this supernatant could not be 
directly tested because of the high pH and molar strength 
of the buffer, which was toxic to cells, after washing the 
pH 9 supernatant with isotonic saline, only low levels of 
mitogenic activity were detected. The specific mitogenic 
activity of the recovered pellet was higher than that of 
the starting material at all doses of axole:mmal protein 
tested (Fig. 1). 
Two chemical treatments of axolemma solubilized 
mitogenic activity for Schwann cells. The mitogen 
solubilized by heparitinase represented 7-10% of the 
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starting protein and 5-10% of the starting mitogenic 
potential (Table 4). Thus, the heparitinase treatment did 
not seem to be selectively removing the mitogen. Heparin 
can displace the axolemmal mitogen for Schwann cells, 
resulting in a soluble extract which is more mitogenic at 
given doses of protein than the recovered pellet and than 
the starting axolemma. Solubilization of the mitogen 
reached a maximum after 2 hr of treatment with heparin; 
treating the axolemma membrane for longer time periods did 
not increase the amount of mitogen solubilized (see Table 
3). Solubilization of the axolemmal mitogen via heparin 
displacement is advantageous in that it results in an 
extract which has a higher specific mitogenic activity than 
the starting material. For the result shown in Figure 6, 
only 6.3% of the starting protein was solubilized by 
heparin treatment, but this soluble extract represented 
14.9% of the starting mitogenic activity (Table 4). Thus 
the soluble extract was approximately threefold enriched in 
specific mitogenic activity compared to the recovered 
(heparin-treated) pellet and 2.4-fold compared to the 
starting axolemma. 
Heparin-solubilized extracts containing 1 mg/ml of 
heparin (assuming that all heparin added remained soluble) 
were found to be mitogenic to Schwann cells. After 
dilution of the extract to obtain the indicated protein 
concentrations as well as dilution due to proliferative 
response assay conditions (Yoshino et al., 1984), Schwann 
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cells would be exposed to 50 ic-g/ml of heparin at the 
highest protein dose of soluble extract shown (fig. 6) . 
As a control, Schwann cells were exposed to 50 ic-g/ml of 
heparin alone and were found to undergo the same extent of 
proliferation as cells receiving medium only (Fig. 6). 
When axolemma was treated with 2 mg/ml of heparin, a 
greater percentage of the starting protein (10.8) was 
solubilized than with the 1 mg/ml treatment of heparin 
(Table 4). However, the protein solubilized was less 
mitogenic than that solubilized by the 1 mg/ml treatment, 
containing only 1.63% of the mitogenic activity (Table 4). 
This result may be due in part to an inhibitory effect of 
heparin in the mi togenic assay. Whereas 50 ic-g/ml of 
heparin added alone to Schwann cells had no effect (Fig. 
6), 100 ic-g/ml of heparin alone, representing the 
concentration of heparin found in the highest dose of 
soluble extract for the 2 mg/ml treatment, inhibited 
Schwann cell mitosis over twofold compared to cells 
receiving medium alone. 
The mitogenic activity of the starting axolemma 
membrane appears to be due to the presence of protein using 
the criteria of heat and trypsin inactivation (DeVries et 
al., 1982). The mitogenic activity of heparin-solubilized 
extract isolated from axolemma membrane also appears to be 
due to the presence of protein, as this mitogenic activity 
is destroyed by heat treatment. Figure 10 shows the effect 
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Figure 10. Heat inactivation of the mitogenic activity of 
heparin extract. Heparin extract was heat inactivated as 
described in Materials and Methods. Heat inactivated 
heparin extract (filled bars) or identical volumes of 
untreated extract (open bars) was added to Schwann cells. 
The open bar at 11 0 11 indicates the effect of hf alone on 
Schwann cells. Each bar represents 5 or more 
determinations, and standard deviations are indicated. 
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of heat inactivation on the mitogenicity of heparin extract 
to Schwann cells. 
Since heat inactivation of the mitogenic activity of 
heparin extract from axolemma indicated the mitogenic 
activity might be due to a protein, we separated the 
extract using SDS-PAGE, and stained for protein. Figure 11 
shows the heparin-solubilized mitogenic extract separated 
on a sodium dodecyl sulfate polyacrylamide gel (10%) in the 
presence of 2-mercaptoethanol. In Figure 11, lanes 3 and 6 
show that heparin treatment of the axolemma results in a 
soluble extract of select molecules. Many of the proteins 
apparent in the untreated axolemma (lanes 1 and 4) are not 
solubilized by heparin. Lane 6 shows that a more diverse 
population of proteins are displaced from the axolemma with 
more concentrated (2 mg/ml) treatments of heparin than in 
lane 3 (1 mg/ml). For the preparation in lane 3, 6.3% of 
the starting protein was solubilized; this represented 
14.9% of the starting mitogenic activity (Table 4). For 
the preparation in lane 6, 10. 8% of the starting protein 
was solubilized; however, this represented only 1.6% of the 
starting mitogenic activity. It is interesting to note 
that in lane 3, one protein band ( indicated at molecular 
weight 50 kDa) appears greatly enriched compared to the 
recovered pellet (lane 2). Lane 6 does not show this 
enriched protein band. 
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1 3 4 5 6 
Figure 11. SDS-polyacrylamide gel electrophoresis of 
heparin-soluble extracts and axolemmal membrane. Gel 
electrophoresis was carried out in 10% acrylamide and 
stained using silver stain as described in Materials and 
Methods. Molecular weights in kilodaltons are indicated at 
the left of the gel. Lane 1 was loaded with 4 7 i.g of 
starting axolemma protein; Lane 2 with 27. 2 i.g of the 
recovered axolemma protein which had been treated with 1 
mg/ml of heparin for 180 min; and Lane 3 with 2. 48 i.g of 
soluble protein displaced by the 1 mg/ml heparin treatment. 
Lane 4 was loaded with 47 i.g of starting axolemma protein; 
Lane 5 with 41.2 i.g of the recovered axolemma protein which 
had been treated with 2 mg/ml of heparin for 240 min; and 
Lane 6 with 5.68 i.g of soluble protein displaced by the 2 
mg/ml treatment. 
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--Isolation of s!,. Monoclonal Antibody which Inhibits the 
Mitogenicity of Axolemrna to Schwann Cells: 
As shown in figure 10, the heparin extract of axolemrna 
contains a selected population of the original membrane 
proteins. Furthermore, as indicated in table 4, the 
heparin extract has a higher specific mitogenic activity 
than the original axolemrna; thus it is enriched in mitogen. 
For these reasons we felt it was worthwhile to produce 
antibodies against the heparin extract in an attempt to 
obtain monoclonal antibodies against the axonal mitogen for 
Schwann cells. 
Our initial criterion for isolating monoclonal 
antibodies that might be relevant for studying the 
axolemrnal mitogen was that these antibodies bind to the 
original starting axolemrnal membrane as determined by ELISA 
techniques. Although the antibodies were raised by using 
the heparin extract of axolemrna, heparin extract was not 
readily available in large enough quantities of protein to 
be used for screening by ELISA (as indicated by table 4, 
the mi togenic heparin extract of axolemma represents only 
6.3% of the starting membrane protein). Furthermore, we 
would be most interested in antibodies that recognized the 
axolemrnal mitogen both in its heparin-solubilized and 
membrane-bound forms. 
Heparin solubilized extract of axolemma which had been 
tested as mitogenic to Schwann cells was injected into one 
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RBF\Dn mouse as indicated in Materials and Methods. 
Fusions were carried out as described in Materials and 
Methods. The fused cells were plated onto three 96-well 
plates, and of these 288 wells, 57 contained viable 
hybridomas. The media supernatants from these mixed 
hybridomas along with the immune serum from the injected 
mouse were tested against 10 i-g/ml of axolemma by ELISA 
techniques. 
As indicated in figure 12, only 2 of the 57 mixed 
hybridomas showed any reactivity whatsoever toward axolemma 
membrane; the immune serum was also reactive, indicating 
that antibodies had been raised to the injected antigen. 
The supernatants from the 55 hybridoma wells not shown in 
figure 12 were found to be identical in reactivity to the 
blank control. The mixed hybridomas in wells 3F8 and 1A5 
were expanded and then cloned by limiting dilution. This 
cloning procedure resulted in the identification of 44 
wells with single cell clones. These monoclonals were 
screened against 10 i-g/ml of axolemma using ELISA 
techniques. 
As shown in figure 13, one monoclonal (1A5-2G3) was 
isolated which was significantly reactive with axolemma. 
The 1A5-2G3 monoclonal antibody was subtyped as IgM K using 
a Boehringer Mannheim mouse immunoglobulin subtype 
identification kit. The mixed hybridoma from which this 
monoclonal was isolated was still reactive; the high 
reactivity of the mixed hybridoma compared to the 
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Figure 12. Reactivity of mixed hybridoma supernatants to 
axolenuna. Hybridomas were produced from a mitogenic 
heparin soluble extract as described in Materials and 
Methods. The supernatants of mixed hybridomas were tested 
undiluted against 10 i.g/ml of axolenuna membrane using ELISA 
techniques as described in Materials and Methods. 
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Figure 13. Reactivity of monoclonal and mixed hybridoma 
supernatants to axolemma. Supernatants from monoclonal 
(1A5-2G3) or mixed (3F8) hybridomas were tested undiluted 
for reactivity against 10 i-g/ml of axolemma using ELISA 
techniques. Hybridomas from 3F8 were cloned out as 
described in Materials and Methods, but none of the clones 
were reactive to axolenm1a, and as indicated the original 
mixed hybridoma of 3F8 (filled bar) was no longer reactive 
to axolemma at the time of cloning. 
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monoclonal indicates the limited growth of the monoclonal 
cells at the time of their isolation. Figure 13 also shows 
that the minor reactivity of mixed hybridoma 3F8 was 
insignificant after cloning; none of the clones from 3F8 
were reactive to axolemma compared to the blank control, 
and the 3F8 mixed hybridoma itself was shown to be non­
reactive to axolemma at the time that clones were isolated. 
Having isolated a hybridoma secreting a monoclonal 
antibody directed against axolemma, we tested whether this 
antibody had any effect on the mitogenicity of axolemma to 
Schwann cells. As shown. in figure 14, monoclonal antibody 
1A5-2G3 inhibited the mitogenic effect of axolemma to 
Schwann cells. The same concentration of antibody did not 
inhibit the mitogenic effect of myelin to Schwann cells. 
The inhibition of mitogenicity did not seem to be due to 
any toxic effect of the antibody alone, as 1A5-2G3 did not 
inhibit proliferation of Schwann cells by itself. 
To investigate the specificity of inhibition of 
mitogenicity to Schwann cells by the antibody 1A5-2G3, we 
used another IgM monoclonal antibody, TIB-103, in similar 
experiments. TIB-103 is directed against Thy 1.1, which is 
found on the surface of fibroblasts and neurons. We 
obtained the hybridoma cells from the American Type Culture 
Collection (ATCC) and collected antibody supernatants from 
the cultures in a similar fashion as for 1A5-2G3. Figure 
15 shows that TIB-103 had no detectable inhibitory effect 
on the mitogenicity of axolemma to Schwann cells. In 
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Figure 14. The mitogenic effect of axolemma but not of 
myelin to Schwann cells is inhibited by 1A5-2G3 antibody. 
The 1A5-2G3 hybridoma supernatant was diluted 1:5 in fetal 
calf serum and incubated with axolemma and myelin as 
indicated in Materials and Methods. The mixture of 
antibody and either axolemma or myelin was added to Schwann 
cells at the indicated protein concentrations (filled 
bars). Other cells of the same culture received identical 
amounts of axolemma or myelin not treated with antibody 
(open bars). Control cells (HF) received media only (open 
bar) or antibody at a 1:5 dilution (filled bar). Each bar 
represents 5 or more determinations and standard deviations 
are indicated. 
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Figure 15. TIB-103 IgM antibody does not inhibit the 
mitogenicity of axolemma to Schwann cells. TIB-103 
hybridoma supernatant diluted 1:5 in HF was incubated with 
axolemma. The antibody-axolemma mixture (filled triangles) 
or axolemma alone (open triangles) was added to Schwann 
cells at the indicated protein concentrations. Control 
cells received media only (open circles) or antibody 
diluted 1:5 in HF (closed circles). Each point represents 
5 or more determinations and standard deviations are 
indicated. Where no error bars appear, standard deviation 
is within the range of the symbols. 
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figure 16 we show that another IgM monoclonal antibody, 
1D3-3Hl2, raised against rat pup CNS microsomes to produce 
murine hybridomas, was also unable to inhibit the mitogenic 
effect of axolemma to Schwann cells. Both TIB-103 and 1D3-
3Hl2 were positive against axolemma using ELISA techniques, 
yet neither inhibited the mitogenic effect of axolemma to 
Schwann cells. 
Figure 17 shows that 1A5-2G3 can also completely 
inhibit the mitogenic activity of the soluble heparin 
extract to Schwann cells at low protein doses. As shown in 
figure 18, 1A5-2G3 can inhibit the mitogenicity of heparin 
extract to Schwann cells at higher protein doses. 
To ensure that the inhibitory effect of 1A5-2G3 was 
not due to non-specific binding of the antibody to protein 
or other components in the axolemma or heparin extract we 
tested the specificity of binding of 1A5-2G3 by ELISA 
techniques. Figure 19 shows the reactivity of 1A5-2G3 to 
rat axolemma, liver membrane, bovine 
heparin as determined by ELISA. At 
serum albumin, and 
the protein doses 
shown, 1A5-2G3 is specific for rat axolemma. It should be 
noted, however, that the amount of both antibody and 
antigen delivered to the ELISA plates is critical: we 
found that too much of antibody or antigen resulted in non­
specific binding. For the result shown in Figure 19, 
greater than 1 i-g/ml of antigen resulted in decreased 
reactivity of 1A5-2G3 to axolemma and increased reactivity 
of the antibody to rat liver microsomes and bovine serum 
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Figure 16. 103-3Hl2 antibody does not inhibit the 
mitogenicity of axolemma to Schwann cells. Hybridoma 
supernatant containing antibody 103-3H12 was diluted 1:5 in 
HF and incubated with axolemma. The antibody-axolemma 
mixture (filled triangles) or axolemma without antibody 
(open triangles) was added to Schwann cells at the 
indicated protein concentrations. Control cells received 
media only (open circles) or antibody at a 1:5 dilution in 
HF. Each point represents 5 or more determinations and 
standard deviations are indicated. Where no error bars 
appear, standard deviation is less than the range occupied 
by the symbols. 
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Figure 17. 1A5-2G3 inhibits the mitogenicity of heparin 
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Figure 18. 1A5-2G3 significantly inhibits the mitogenicity 
of heparin extract: dose response curve. 1A5-2G3 at a 1:5 
dilution was incubated with heparin extract at the 
indicated protein concentrations. Open circles show the 
mitogenic response of Schwann cells to untreated heparin 
extract; closed circles show mitogenic response to heparin 
extract treated with antibody. Open triangles show the 
effect of hf alone on Schwann cell; antibody alone had an 
identical mitogenic effect on Schwann cells as hf. Each 
point represents 5 or more determinations and standard 
deviations are indicated. Where no error bars appear, 
standard deviation is less than the range occupied by the 
symbol. 
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supernatant diluted 1:100 was reacted 
the indicated concentrations using 
described in Materials and Methods. 
to axolemma, liver 
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with the antigens at 
ELISA techniques as 
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albumin. It is of importance to note the lack of binding 
of 1A5-2G3 to heparin shown in figure 19. Presumably, 
since heparin extracts used to immunize mice contain large 
amounts of soluble heparin, isolated antibodies may have 
recognized glycosaminoglycan epitopes; the ELISA results 
shown in figure 19 indicate that 1A5-2G3 does not bind to 
heparin. 
Although 1A5-2G3 was able to inhibit the mitogenicity 
of both untreated axolemma and the soluble heparin 
extracts, only at the lowest doses of heparin extracts 
could we achieve total inhibition of the mitogenic effect 
on Schwann cells. Furthermore, since we were using small 
dilutions of hybridoma supernatants (1:5 in figures 17 and 
18) we could not increase the amount of antibody used 
without concentrating the supernatants. 
We attempted to concentrate 1A5-2G3 by passing 
hybridoma medium through XM300 amicon filters as described 
in methods. Our rationale was that the large molecular 
weight of IgM (>900 kDa) would prevent passage through the 
filter while other proteins in the hybridoma medium would 
pass through, thus concentrating the IgM in the retained 
volume. However, at that time we were growing the 1A5-2G3 
hybridoma in HF with 15% fetal calf serum. When this 
medium was concentrated using the XM300 amicon filter, we 
found it was mitogenic to Schwann cells in comparison to 
background levels of proliferation, which were cells 
receiving HF medium with 10% fetal calf serum. Thus, the 
93 
concentrated 1A5-2G3 alone was mitogenic to Schwann cells, 
confounding the interpretation of its inhibitory effect on 
the mitogenicity of axolemma to Schwann cells. The most 
likely explanation for this result was that the fetal calf 
serum in the hybridoma supernatants contained growth 
factors for Schwann cells; concentrating the supernatant 
also increased the concentration of these growth factors, 
causing the concentrated supernatant to be mitogenic to 
Schwann cells compared to HF, which contains 10% fetal calf 
serum. 
Since no convenient methods of purifying IgM were 
available we attempted to grow the 1A5-2G3 hybridoma in a 
defined medium. Medium with defined components would allow 
concentration without the mitogenic effect on Schwann cells 
seen for fetal calf serum (which contains undefined 
mitogenic factors). Figure 20 shows that when the 1A5-2G3 
hybridomas were grown in a defined medium developed by Chen 
and Devries (1989), antibody was produced which 
specifically bound to axolemma compared to rat liver 
microsomes as determined by ELISA. Figure 21 shows that 
1A5-2G3 produced in defined medium and concentrated using 
the Amicon XM300 filters retains specificity to axolemma. 
The concentrated antibody shown in figure 21 is reactive to 
axolemma at dilutions up to 700-fold; the concentrated 
antibody does not show reactivity to rat liver microsomes 
until approximately 200-fold dilutions. It is important to 
note that the specificity of binding to axolemma (at least 
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REACTIVITY OF 1A5-2G3 IN DEFINED MEDIA (UNDILUTED) 
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Figure 20. Preferential reactivity of 1A5-2G3 in defined 
media to axolemma compared to liver microsomes. Undiluted 
1A5-2G3 hybridoma supernatant grown in defined media as 
described in Materials and Methods was reacted with rat 
axolemma or liver microsomes at 1 i-q/ml antigen 
concentration using ELISA techniques. Each bar represents 
2 determinations and standard deviations are indicated. 
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Figure 21. 1A5-2G3 in concentrated defined media 
preferentially reacts with axolemma compared with liver 
microsomes. 1A5-2G3 hybridoma supernatant grown in defined 
media and concentrated 9-fold by filtration as described in 
Materials and Methods was reacted at the indicated antibody 
dilutions with rat axolemma (open circles) or liver 
microsomes (closed circles) at antigen concentration of 1 
J.9'/ml using ELISA techniques. Each point represents 2 
determinations; standard deviation is less than the range 
occupied by the symbols. 
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by ELISA techniques) depends upon both antibody and antigen 
concentration. We found that at very high antigen 
concentrations specificity of binding was lost. 
Figures 22 A-C show that 1A5-2G3 grown in defined 
media retains the capability to inhibit the mitogenic 
effect of axolemma on Schwann cells. The antibody alone 
shows a slight inhibitory effect on Schwann cell 
proliferation; however, even where no inhibition of 
proliferation by the antibody alone is seen, 1A5-2G3 still 
significantly inhibits the mitogenic effect of axolemma on 
Schwann cells. Figure 22 A shows that at an axolemmal 
protein concentration of 168 JJ:J/ml, 
1A5-2G3 hybridoma supernatant almost 
the mitogenic effect of axolemma 
approximately 88% of the mitogenic 
undiluted (straight) 
completely inhibits 
on Schwann cells; 
effect is inhibited. 
Decreasing the axolemmal protein concentration to 84 JJ:J/ml 
(Figure 22 B) allows undiluted 1A5-2G3 to completely 
inhibit the mitogenic effect of axolemma on Schwann cells. 
At 42 JJ:J of axolemmal protein/ml (Figure 22 C) , 1A5-2G3 
diluted 1:2 with HF can completely inhibit the mitogenic 
effect of axolemma to Schwann cells. The inhibition of the 
mitogenic effect of axolemma on Schwann cells by 1A5-2G3 is 
thus dependent upon both mitogen and antibody 
concentration. For a given dose of axolemma, increased 
amounts of antibody inhibit more mitogenicity; similarly, a 
given amount of antibody (for example, undiluted) inhibits 
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Figure 22a. 1A5-2G3 in defined media inhibits the 
mitogenicity of axolemma (168 i-g/ml). 1A5-2G3 in defined 
media was incubated at the indicated dilutions with 168 
i-g/ml of axolemma. Open bars indicate the mitogenic effect 
of hf alone on Schwann cells; closed bars represent the 
effect of antibody alone at the indicated dilution; hatched 
bars represent the mitogenic effect of 168 i-g/ml of 
axolemma treated with the dilution of antibody indicated. 
Each bar represents five or more determinations; standard 
deviations are indicated. Where no error bars appear, 
standard deviation is less than the width of the top of the 
bar. 
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Figure 22b. 1A5-2G3 in defined media inhibits the 
mitogenicity of axolemma (84 i-q/ml). 1A5-2G3 grown in 
defined media was incubated at the indicated dilutions with 
axolemma (84 i-q/ml). Open bars indicate mitogenic effect 
of hf only; closed bars represent the effect of antibody 
at the indicated dilutions; hatched bars represent the 
mitogenicity of axolemma (84 i-q/ml) treated with the 
indicated dilution of antibody. Each bar represents 5 or 
more determinations, and standard deviations are indicated. 
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Figure 22c. 1A5-2G3 in defined media inhibits the 
mi togenici ty of axolemma ( 42 1,g/ml) . 1A5-2G3 grown in 
defined media at the indicated dilution was incubated with 
axolemma at 42 1,g/ml. Open bars indicate the mitogenic 
effect of hf only; closed bars represent the effect of 
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treated with antibody at the indicated dilutions. Each bar 
represents 5 or more determinations and standard deviations 
are indicated. 
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smaller doses of axolemma to a greater extent 'than larger 
doses. 
Figures 23 A-C show that 1A5-2G3 grown in defined 
media and then concentrated by Amicon filters (as described 
in methods) retains the ability to inhibit the mitogenicity 
of axolemma to Schwann cells. We found that the inhibition 
of concentrated 1A5-2G3 grown in defined media was variable 
and dependent upon treatment conditions. For example, the 
inhibition seen in figures 23 A-C using concentrated 1A5-
2G3 is not as extensive as that seen in figures 22 A-C 
using unconcentrated antibody. The reasons for this 
variability in inhibition of mitogenic activity were not 
always clear. 
Despite the complex behavior of the concentrated 
antibody, the results shown in figure 23 indicated that 
molecular weight filtration could be used as a method for 
concentrating and purifying to a certain extent the IgM 
1A5-2G3. Since the antibody was now being produced in 
hybridoma cultures grown in defined medium, this medium 
could be concentrated by the Amicon XM300 filter, allowing 
most of the small molecular weight proteins (<300 kDa) to 
be removed and the 1A5-2G3 IgM proteins (>900 kDa) to be 
retained and thus concentrated. These processes would be 
important if the antibody were to be used for affinity 
columns, iodination, and other coupling procedures 
requiring homogeneous molecular species. 
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Figure 23a. 1A5-2G3 in concentrated defined media inhibits 
the mitogenicity of axolemma (168 i.g/ml). 1A5-2G3 grown in 
defined media and concentrated 9-fold by filtration as 
described in Materials and Methods was incubated at the 
indicated dilutions with axolemma (168 i.g/ml). Open bars 
indicate the mitogenic effect of hf only; closed bars 
represent the effect of antibody alone at the indicated 
dilutions; hatched bars represent the mitogenic effect of 
axolemma (168 i.g/ml) treated with antibody at the indicated 
dilutions. Each point represents 5 or more determinations 
and standard deviations are indicated. 
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antibody at the indicated dilutions. Each bar represents 5 
or more determinations; standard deviations are indicated. 
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Figure 23c. 1A5-2G3 in concentrated defined media inhibits 
the mitogenicity of axolemma (42 µJ/ml). 1A5-2G3 grown in 
defined media and concentrated 9-fold by filtration was 
incubated at the indicated dilutions with axolemma (42 
µJ/ml). Open bars indicate the mitogenic effect of hf 
only; filled bars represent the effect of antibody alone 
at the indicated dilutions; hatched bars represent the 
mitogenic effect of axolemma (42 µJ/ml) treated with 
antibody at the indicated dilutions. Each bar represents 5 
or more determinations and standard deviations are 
indicated. 
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To determine whether 1A5-2G3 was inhibiting the 
mitogenic effect of axolemma on Schwann cells at the site 
of the cell or at the site of the membrane, we treated 
Schwann cell cultures with 1A5-2G3 antibody for 24 hours. 
Separate wells on the same culture plate of Schwann cells 
received HF only. 
cell cultures were 
After removing antibody (or HF), Schwann 
treated with axolemma. As shown in 
figure 24, pretreatment of Schwann cell cultures with 1A5-
2G3 at concentrations used in previous experiments, does 
not prevent proliferative response to axolemma. In the 
experiments described earlier, axolemma and 1A5-2G3 
remained on the Schwann cell cultures for the duration of 
the treatment. It could be argued that the results 
obtained were due to 1A5-2G3 somehow inhibiting at the cell 
surface rather than binding to the axolemma; pretreatment 
of the Schwann cell cultures with 1A5-2G3 seems to exclude 
this possibility. This result, along with those from ELISA 
indicate that 1A5-2G3 is binding to axolemma, and 
inhibiting the mitogenic effect of axolemma to Schwann 
cells at the site of the membrane, possibly by binding to 
the mitogen itself. 
--1A5-2G3 Immunoaffinity Isolation of the Axonal Mitogen 
for Schwann Cells: 
The above results suggested that 1A5-2G3 might be used 
as a tool for isolating the axonal mitogen for Schwann 
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SCHWANN CELL MITOSIS IN RESPONSE TO AXOLEMMA 
IS NOT BLOCKED BY PRETREATMENT OF CELLS WITH 1A5-2G3 
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Figure 24. Schwann cell mitosis in response to axolemma is 
not inhibited by pretreatment of cells with 1A5-2G3. 
Schwann cell cultures were pretreated with. hf or 1A5-2G3 in 
defined media concentrated 9-fold by filtration at a 
dilution of 1:16. This dilution of 1A5-2G3 was previously 
shown to inhibit the mitogenicity of axolemma when axolemma 
was treated with antibody. Open triangles indicate the 
mitogenicity of axolemma on untreated cultures at the 
protein concentrations shown; closed triangles indicate the 
effect of axolemma on Schwann cell cultures pretreated with 
a 1:16 dilution of 1A5-2G3. Open circles indicate 
proliferation of Schwann cell cultures pretreated with hf; 
filled circles indicate proliferation of cultures 
pretreated with 1A5-2G3. Each point represents 5 or more 
determinations; standard deviations are indicated. 
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cells: 1A5-2G3 bound to axolemma as determined by ELISA 
techniques; it inhibited the mitogenicity of axolemma and 
the soluble heparin extract to Schwann cells; and it did 
not prevent Schwann cells pretreated with antibody from 
proliferating in response to axolemma. 1A5-2G3 grown in 
defined medium and filtered as described in methods 
provided us a source of concentrated antibody which was 
also purified to the extent that small molecular weight 
proteins were removed. We coupled concentrated 1A5-2G3 to 
activated CH-Sepharose 4B as described in methods. This 
procedure provided us with an affinity column which we used 
to attempt isolation of the mitogenic activity of the 
soluble heparin extract. 
Mitogenic soluble heparin extract was loaded onto the 
affinity column as described in methods. The column was 
centrifuged, eluted fractions collected, and washed with 
buffer or elution reagents as described in methods. Figure 
25A shows that when mitogenic soluble heparin extract was 
loaded onto the 1A5-2G3 affinity column, no mitogenic 
activity was recovered from the column. Gel 
electrophoresis of the eluted fractions using silver 
staining indicated that the only detectable proteins eluted 
were in wash-through fractions 4-6. Treatment of the 
column with glycine/HCl buffer ( O. 1 M pH 2. 5) failed to 
elute any detectable proteins. This result indicated that 
the mitogenic activity of the soluble heparin extract had 
bound to the affinity column. Because of the 
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Figure 25a. Mitogenicity of fractions eluted from 1A5-2G3 
affinity column. Mitogenic heparin extract was loaded onto 
a 1A5-2G3 affinity column in a volume of 250 µl as 
described in Materials and Methods. Eluted volumes 
collected were 250 µl each. Heparin extract loaded onto 
the column (8.75 i-g/ml) gave a mitogenic response of 3699 ± 
510 dpm; a 2-fold dilution (4.375 i-g/ml) gave a mitogenic 
response of 3181 ± 405 dpm. Open circles indicate the 
mitogenic effect of hf alone (1873 ± 387 dpm); open 
triangles indicate the mitogenic effect of fractions eluted 
from the affinity column. Each point represents 2 or more 
determinati,ons; standard deviations are indicated. Where 
no error bars appear, the standard deviation is less than 
the range occupied by the symbol. 
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centrifugation steps, eluted fractions were of the same 
volume as those loaded; thus the loss of mitogenic activity 
could not be due ·to dilution. Furthermore, all eluted 
fractions which contained detectable protein by silver 
stain were in the wash buffer: the glycine/HCl buffer 
eluted no detectable proteins, so the loss of mitogenic 
activity was most likely not due to inactivation by acid. 
It is always possible, however, that a mi togenic factor 
could remain undetected by protein staining if in small 
enough quantities. 
Figure 25B shows the pH profile of the eluted 
fractions from the column. Glycine/HCl elution buffer was 
applied starting at fraction #5, but the pH of eluted 
fractions did not change �ntil fraction #9. Thus there is 
a lag over the length of the column between what is loaded 
and what is eluted. As mentioned above, protein was 
detected only in fractions 4-6; these should not have been 
affected by pH changes. 
The same 1A5-2G3 affinity column was treated with 
cycles of wash buffer and elution reagents as described 
above; elution reagents included: 0.15 M NaCl + ammonia 
(pH 11), 1 M HCl, and 5 mg/ml heparin. None of these 
elution reagents lead to release of detectable protein from 
the affinity column as determined by silver staining. 
However, when the 1A5-2G3 affinity column was treated with 
6 M urea (pH 1.8), a single polypeptide species was eluted 
as detected by silver staining (figure 26). This result 
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Figure 25b. pH profile of fractions eluted from 1A5-2G3 
affinity column. Fractions were eluted from 1A5-2G3 
affinity column with glycine/HCl buffer (0.1 M pH 2.5) as 
indicated in Materials and Methods. pH of eluted fractions 
was determined by litmus paper. Arrowheads indicate where 
glycine/HCl buffer was applied (2.5) and where column was 
equilibrated back to pH 8 with wash buffer ( 0.1 M Tris + 
0.5 M NaCl) (8.0). 
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Figure 2 6. Elution of a single polypeptide species from 
1A5-2G3 column using urea. A 1A5-2G3 column which had been 
previously loaded with heparin extract was treated with 
wash buffer: 0.1 M Tris + 0.5 M NaCl, pH 8 (fractions 1-
4); 6 M urea, pH 1.8 was then applied to the column 
(fractions 5-12); the column was then equilibrated with 
wash buffer as above (fractions 13-20). The eluted 
fractions indicated were separated on SDS-PAGE in a 11-23% 
acrylamide gradient and stained using silver stain; 
molecular weights are indicated in kilodal tons. The only 
detectable protein by silver staining technique occurred in 
fraction 8; however, no detectable difference existed 
between SDS-PAGE of mitogenic heparin extract and extract 
protein not binding to the column. The pH of eluted 
fractions was 8. O for fractions 1-8; 1. 8 for fractions 9-
16; 3.0 for fraction 17; 5.0 for fraction 18; 7.0 for 
fraction 19; and 8.0 for fraction 20. 
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indicated the specificity of the 1A5-2G3 column; only one 
fraction contained detectable protein eluted from the 
column, and the one fraction contained only one polypeptide 
species. 
Figure 27 shows that after dialysis and sterile 
filtration, fraction #8 shown in figure 26 is retained. 
Due to dilution from dialysis and filtration the protein 
content is decreased. In addition, we see that lane 1 in 
figure 27, containing the same material as fraction #8 in 
figure 26, shows minor bands not seen previously. This is 
due to the longer development time used for the silver 
staining in figure 27 to allow for detection of the bands 
in lanes 2 and 3. The minor bands seen in lane 1 of figure 
27 could be related to the major band in two ways: 1) the 
higher molecular weight band could be a dimer of the main 
band; 2) the lower molecular weight bands could be 
degradation products of the main band (this could occur due 
to the different acid and base treatments to which the 
column had been exposed). A third possibility is that the 
minor bands seen in lane 1 are not related to the major 
band, and are proteins which bind to a small degree to the 
column. 
Detection of a single protein band in lane 3 of 
figure 27 indicated that the major band in lane 1 could 
survive dialysis and sterile filtration and thus could be 
tested for mitogenicity to Schwann cells. Not 
surprisingly, when tested on Schwann cells, eluted fraction 
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Figure 27. Dialysis and sterile filtration of protein 
eluted from 1A5-2G3 affinity column. Protein was eluted 
from 1A5-2G3 affinity column using urea as described; 
fraction 8, which contained the eluted protein, was 
separated by SOS-PAGE on an 11-23% acrylamide gradient and 
stained using silver stain. Lane 1 indicates the eluted 
fraction in urea; lane 2 dialysed fraction; lane 3 dialysed 
fraction which had been sterile filtered. Molecular 
weights are indicated in kilodaltons. 
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#8 was not mitogenic. If the single protein band seen in 
fraction #8 were the mitogen, 6 M urea most likely 
denatured it; denaturation often times irreversibly 
inactivates proteins. This result left us with the paradox 
of tight binding to the affinity column: the tight binding 
might allow for specificity, but it might also necessitate 
use of harsh denaturants such as urea to uncouple the 
ligand from the antibody. 
The concentrated 1AS-2G3 appears to inhibit the 
mitogenicity of axolemma to Schwann cells in a manner 
similar to immunoprecipitation titrations; that is, 
high concentrations of antibody actually inhibit 
very 
the 
mitogenicity of axolemma less effectively than lower 
concentrations. This type of behavior is shown in figure 
28. Concentrated· 1AS-2G3 was incubated with axolemma as 
described; a 100-fold dilution of the antibody had a 
greater inhibitory effect than a SO-fold dilution on the 
mitogenicity of axolemma to Schwann cells. It can be seen 
that at the lowest concentration of axolemma tested, the 
SO-fold dilution of 1AS-2G3 had no perceptible inhibitory 
effect, while the 100-fold dilution of antibody inhibited 
almost 60% of the mitogenicity of axolemma. 
Despite the complicated behavior of the concentrated 
antibody and the harsh conditions needed to remove proteins 
from the affinity column, we attempted to demonstrate that 
the results we obtained were not due to nonspecific IgM 
binding properties. Purified IgM recognizing an undefined 
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Figure 28. Inhibition of axolemmal mitogenicity by 1A5-2G3 
in concentrated defined media. 1A5-2G3 grown in defined 
media and concentrated 40-fold by filtration was incubated 
at the indicated dilutions with axolemma. The mitogenic 
response of axolemma treated with antibody at the indicated 
dilutions was compared with untreated axolemma at the same 
protein doses to calculate the % inhibition of 
proliferation due to antibody treatment. No detectable 
inhibition of proliferation was observed at 13. 5 i-g/ml of 
axolemmal protein using a 1:50 dilution of antibody. 
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epitope (Sigma TEPC 183) was used as a nonspecific IgM to 
investigate the specificity of inhibition of 1A5-2G3. 
Figure 29 shows that 1A5-2G3 inhibits the mitogenicity 
of axolemma to Schwann cells to a greater extent than does 
Sigma IgM. The same amount of 1A5-2G3 and Sigma IgM was 
used for inhibiting as determined by ELISA. 
appears to have a slight inhibitory effect, 
significantly less than the effect of 1A5-2G3. 
Sigma IgM 
but it is 
Further support for the specificity of 1A5-2G3 as an 
affinity tool for isolating the axonal mitogen for Schwann 
cells is shown in figure 30. As indicated in figure 30, 
almost 90% of the mitogenic activity associated with the 
Sigma IgM-coupled resin could be recovered in the 
supernatant; this indicated that little or no mitogenic 
activity bound to the Sigma IgM resin. In contrast, just 
under 50% of the mitogenic activity applied associated with 
the 1A5-2G3-coupled resin could be recovered in the 
supernatant; thus, mitogenic activity bound to the 1A5-2G3 
resin. 
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Figure 29. Schwann cell mitosis in response to axolemma is 
inhibited by 1A5-2G3 to a greater extent than by non­
specific IgM. Axolemma was treated with 1A5-2G3 or Sigma 
IgM TEPC 183 (as a non-specific IgM) at the indicated 
antibody dilutions. ELISA techniques determined that the 
indicated dilutions of antibody contained the same amount 
of IgM. Open bars represent the mitogenic effect of 
axolemma at the indicated protein concentrations; closed 
bars indicate the effect of axolemma treated with 1A5-2G3; 
crossed bars indicate the effect of axolemma treated with 
Sigma IgM. Each bar represents 5 or more determinations 
and standard deviations are indicated. 
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Figure 30. Recovery of mitogenic activity from 1A5-2G3 and 
Sigma IgM columns. Mitogenic heparin extract was added to 
1A5-2G3 and Sigma IgM resins as indicated in Materials and 
Methods. Resins were centrifuged and the supernatants 
removed and sterile filtered. Resins were washed as 
described and supernatants collected and sterile filtered. 
Supernatants from the recovered resins were tested for 
mitogenicity and compared with the mitogenicity of the 
starting heparin extract to determine % of starting 
mitogenic activity recovered from each resin. No 
detectable mitogenic activity was recovered from fraction 3 
or 4 of 1A5-2G3 resin (filled bars) or from fraction 4 of 
the Sigma IgM resin (open bars). The total cumulative 
mitogenic activity recovered from each resin is indicated 
as "total". 
DISCUSSION 
In this discussion I will relate our in vitro studies 
of axonal stimulation of Schwann cell proliferation to in 
vivo events. Our results from biochemical characterization 
of the axolemmal mitogen for Schwann cells will be 
presented and summarized in the form of a model depicting 
the molecular nature of the mitogen. Finally, the evidence 
of a monoclonal antibody which inhibits the mitogenicity of 
axolemma to Schwann cells will be discussed as an important 
tool for isolating to homogeneity the molecule responsible 
for axonal promotion of Schwann cell proliferation. 
Base extraction of non-mitogenic axolemmal proteins: 
The studies of Sobue and Pleasure (1985) had shown 
that the adhesion of axolemmal fragments to Schwann cells 
was closely linked to axolemmal induction of Schwann cell 
mitosis. Using 125I-labelled axolemma, Sobue and Pleasure 
(1985) showed that adhesion of axolemmal fragments to 
Schwann cells was specific and time dependent. In an 
attempt to extend the studies of Sobue and Pleasure (1985), 
we fluorescently labelled axolemma with FITC and developed 
a fluorescent binding assay to measure the extent of 
118 
119 
binding of axolemma membrane to Schwann cells in culture. 
Further investigations using the fluorescently labelled 
axolemma led us to an important control experiment: if 
fluorescently labelled axolemma were to serve as a valuable 
probe to how normal axolemma interacted with Schwann cells, 
then methods used to fluorescently label the axolemma 
should not drastically alter its properties. Meador­
Woodruff et al. (1985) had shown that FITC conjugation did 
not alter the mitogenicity of axolemma-enriched fractions; 
thus we had a rationale for correlating results using 
unlabelled axolemma with those using FITC labelled 
axolemma. 
One difference between the protocol used by Meador­
Woodruff et al. (1985) and the method we used to conjugate 
FITC to axolemma was the use of pH 9 buffer. In the 
studies of Meador-Woodruff et al. (1985), solid FITC 
powder was added to axolemma which had been treated with 
0.075 M final concentration of sodium carbonate/bicarbonate 
buffer at pH 9. As indicated above, Meador-Woodruff et al. 
(1985) found that this treatment did not alter the 
mitogenicity of axolemma. We wanted to ensure that the 
FITC-treated axolemma remained sterile, so we dissolved the 
FITC powder in 0.5 M sodium carbonate/bicarbonate buffer at 
pH 9, and then sterile filtered the solution. The sterile 
FITC was then added to axolemma to make the mixture 0.275 M 
in final sodium carbonate/bicarbonate buffer. All other 
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aspects of the treatment were.similar to those carried out 
by Meador-Woodruff et al. (1985). 
When we treated axolemma with the same buffer used to 
conjugate FITC to axolemma (0. 27 M sodium 
carbonate/bicarbonate, pH 9) in the absence of fluor, we 
obtained a surprising result. Treatment of axolemma with 
0. 27 M sodium carbonate/bicarbonate buffer at pH 9 resulted 
in a recovered pellet containing 50% of the starting 
protein and 95% of the starting mitogenic activity. This 
result indicated that the axolemmal mitogen is ionically 
unchanged at pH 9; thus, it will remain associated with the 
membrane while other proteins are removed. 
Alkaline extraction has been previously shown to 
solubilize membrane proteins from red blood cells by the 
use of NaOH (Steck and Yu, 1973) and from rat liver 
microsomes using Na
2
co3 (Fujiki et al., 1982). Philipson 
et al. (1987) have shown that alkaline extraction of canine 
cardiac sarcolemmal vesicles using NaOH results in 
extraction of 33% of the membrane protein. Reconstitution 
of the alkaline extracted membranes resulted in recovery of 
50% of the protein of vesicles reconstituted from control 
sarcolemma, yet total Na+-ca2+ exchange activity recovered 
was unchanged; the authors thus postulated that high pH 
extracts specific proteins from the membrane, leaving the 
protein(s) responsible for Na+-ca2+ exchange fully active 
and retained in the membrane. 
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Although the pH 9 supernatant could not directly be 
tested for mitogenicity on Schwann cells due to the 
toxicity and molar strength of the buffer, washing with 
isotonic saline in a 10 kDa molecular weight cutoff 
Centricon tube allowed the supernatant to be added to cells 
without toxic effect. The pH 9 extracted supernatant of 
axolemma contains 50% of the protein in the starting 
axolemma, yet after washing with isotonic saline, the 
mitogenicity of this supernatant represents only 8 ± 2% of 
the mitogenicity of the starting axolemma. This result 
further supports the idea that pH 9 extraction of axolemma 
leaves the vast majority of mitogen undisturbed and 
membrane-bound while removing non-mitogenic protein from 
the axolemmal membrane. Retention of binding of the 
axolemmal mitogen to the membrane after pH 9 extraction 
indicates that the mitogen may be basic in nature and thus 
contain regions that are highly positively charged. For 
example, in proteins the only ionizable groups of amino 
acids which would have positive charge remaining at pH 9 
would be the lysyl amino group of lysine (PKa: 10.8) and 
the guanidine group of arginine (PKa: 12.5) (Palmer, 
1985). Retention of the axolemmal mitogen in the membrane 
after base extraction might therefore indicate that the 
molecule, if a protein, contains large numbers of lysines 
and/or arginines. 
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Enzymatic cleavage of sulfated proteoglycans solubilizes 
axolemmal mitogenic activity: 
The idea that the axolemmal mitogen for Schwann cells 
had basic characteristics and contained regions that were 
highly positively charged had added significance in light 
of experimental result of Ratner et al. (1985). The work 
of Ratner et al. (1985) demonstrated that interfering with 
proteoglycan synthesis of neurons or treatment of neuritic 
membranes with heparitinase significantly depleted the 
mitogenicity of these membranes to cultured Schwann cells. 
Since heparitinase cleaves the glycosidic bonds of sulfated 
. glycosaminoglycans, we postulated that heparitinase might 
deplete the mitogenicity of neurite membranes to Schwann 
cells (Ratner et al., 1985) by releasing a positively 
charged mitogen bound to the sulfated heparan sulfate 
proteoglycans. 
When axolemma was treated with heparitinase, a soluble 
extract was obtained which was mitogenic to Schwann cells. 
Solubilization of mitogenic activity for Schwann cells was 
significant in itself; earlier attempts to solubilize the 
mitogenicity of axolemma to Schwann cells using traditional 
detergents were not consistently reproducible (Cassel et 
al., 1982; Dinneen, 1985). Glaser (1978) predicted that 
"the greatest obstacle in all of these systems will no 
doubt be the difficulty in fractionating membrane proteins 
by novel techniques so that they can still interact with 
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live cells while avoiding the toxic effects of detergents." 
It' seems that the toxicity of detergents to Schwann cells 
accounts for the variable results of Cassel et al. (1982) 
and Dinneen (1985) in attempting to solubilize the 
mitogenicity of axolemma to Schwann cells. Even though the 
work of Cassel et al. ( 1982) included steps to remove 
detergent by dialysis, axolemma extracts solubilized by 
deoxycholate sometimes appeared toxic to the cells. 
Another explanation for why detergents might not allow 
active soluble mitogen to be recovered could lie in the 
tendency for some detergents to complex with proteins, 
thereby unfolding and inactivating them by denaturation 
(Helenius and Simons, 1975). 
Although heparitinase solubilized some of the 
mitogenic activity of axolemma to Schwann cells, the 
heparitinase treated pellet was also still mitogenic. 
Furthermore, heparitinase-solubilized extracts were more 
mitogenic to Schwann cells as the dose of protein was 
decreased. This appeared to be due to the toxic effect of 
heparitinase at high doses; as the dose of soluble extract 
was increased the amount of heparitinase (all of which 
presumably remained soluble) was also increased, and had 
adverse effects on the cells. Nevertheless, solubilization 
of the mitogenicity of axolemma to Schwann cells using 
heparitinase helped further characterize the nature of the 
mitogen. Results using heparitinase indicated 1) that 
cleavage of the glycosidic bonds of sulfated proteoglycans 
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released the mitogen from these proteoglycans and/or 2) 
cleavage of the glycosidic bonds released the sulfated 
proteoglycan-mitogen complex from the surface of the 
axolemmal membrane. Figure 31 illustrates a model which we 
developed to explain the molecular aspects of the axolemmal 
mitogen and its association with the membrane surface. We 
can see that the effect of breaking the glycosidic bonds of 
sulfated proteoglycans (by use of heparitinase) on 
releasing the mitogen from the membrane surface depends on 
how the sulfated proteoglycan is associated with the axonal 
membrane. Kjellen et al. (1980, 1981) showed that 
proteoglycans which are associated with the membrane 
ionically or plasma-membrane anchored can both exist on the 
same tissue surface. By cleaving the glycosidic bonds of 
sulfated proteoglycans found in axolemma, we can see from 
figure 31 that the mitogen might be released from the 
proteoglycan itself, or if the proteoglycan is ionically 
associated with the axolemmal surface, the mitogen­
proteoglycan complex might be released. 
Heparin solubilizes the mitogenic activity of axolemma: 
Considering the result of heparitinase treatments 
of axolemma along with that of the pH 9 experiments, (which 
indicated that the mitogen could be ionically associated 
with the sulfated proteoglycans) we predicted that the 
mitogen could be displaced by heparin. Kraemer (1977) 
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Figure 31. Molecular model of interaction of axolemmal 
mitogen with surface heparan sulfate proteoglycan. The 
axolemmal mitogen is represented as a positively charged 
molecule (rectangle) associated with negatively charged 
heparan sulfate proteoglycan. Heparan sulfate proteoglycan 
can be anchored in the lipid bilayer (right) or ionically 
associated with the membrane surface (left). 
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showed that heparin can displace heparan sulfate frpm cell 
surfaces. In addition, heparin shares structural 
homologies with heparan sulfate (Alberts et al., 1983), 
including carbohydrate composition of the repeating 
disaccharide units, and thus might serve as an effective 
competitor for binding the mitogen molecule. Since heparin 
is more highly sulfated than heparan sulfate (Margolis and 
Margolis, 1979), it should be an effective chelator of any 
positively charged molecules associated with heparan 
sulfate proteoglycans. 
As shown in figure 6, treatment of axolemma with 
heparin results in solubilization of mitogenic 
Although the heparin treated axolenuna pellet 
activity. 
is still 
mitogenic to Schwann cells, the mitogenic heparin extract 
has a higher specific mitogenic activity than the treated 
or starting axolenuna. Thus, heparin treatment of axolemma 
differentially displaces the mitogen: non-mitogenic 
proteins are displaced by heparin too, but the mi togenic 
activity is enriched in the heparin extract. As shown in 
figure 11, gel electrophoresis of the heparin extract 
indicates one protein which is most highly enriched in 
comparison to the heparin treated and untreated axolenuna; 
whether this enriched protein is responsible for the 
correlated enrichment in mitogenic activity requires 
further investigation. Recent preliminary findings 
(Decoster and Devries, unpublished observations) indicate 
that when mitogenic heparin extract is separated into three 
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molecular weight fractions by Centricon filtration (see 
Materials and Methods), mitogenic activity is recovered 
only in the >30 kDa fraction. Further analysis of these 
separated fractions is required to interpret this result: 
the mitogen itself could be >30 kDa in molecular weight, or 
a <30 kDa mitogen might have complexed with heparin to 
remain above the filter. 
In contrast to the possible inhibitory effect of 
heparitinase, heparin itself has no effect on Schwann cell 
proliferation at the doses of protein shown in Figure 6 (50 
1-'J of heparin/ml at the highest dose of soluble extract 
protein). This result differs from that of Ratner et al. 
( 1988) , who found that a neuronal cell surface protein 
obtained from neonatal rat brain was mitogenic to Schwann 
cells, but that this mitogenic effect was half maximally 
inhibited by the presence of 0.5-0.7 µJ of heparin/ml. One 
possible explanation for this difference is that the 
neuronal 
altered. 
mitogen for Schwann cells is 
Heparin has been shown to 
developmentally 
potentiate the 
mitogenicity of acidic fibroblast growth factor more than 
100-fold (Gimenez-Gallego et al., 1986) and to protect both 
acidic and basic fibroblast growth factor from inactivation 
(Gospodarowicz and Cheng, 1986). Recent results of Chen 
and Devries have shown that the heparin extract of axolemma 
which is mitogenic to oligodendrocytes (Chen and Devries 
1989a) can be protected from heat inactivation by heparin. 
In addition, as shown in Figure 10 of Results, the 
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mitogenic activity of heparin extract to Schwann cells does 
not appear to be completely destroyed be heat treatment of 
100° C for 10 minutes. In contrast, the mitogenicity of 
axolemmal membrane to Schwann cells is completely destroyed 
by heating at 00° c for 10 minutes (Devries et al., 1982). 
Thus, slight developmental alterations in the neuronal 
mitogen for Schwann cells might drastically change the 
mitogenic effect in the pres�nce of heparin. 
Solubilization of mitogenic activity from axolemma 
using heparin provides a third method of characterizing the 
molecular nature of the mitogen. Evidence from pH 9 
extraction, heparitinase treatment, and heparin treatment 
of axolemma all support the molecular model for the axonal 
mitogen to Schwann cells shown in figure 31. By comparing 
the effects of the different treatments on the mitogenicity 
of axolemma to Schwann cells, we can provide the following 
"clues" about the molecular nature of the mitogenic 
molecule: 1) Extraction of non-mitogenic protein from 
axolemma by pH 9 treatment indicated that the axonal 
mitogen is basic in character; some region of the molecule 
may be highly positively charged. 2) Treatment of axolemma 
with heparitinase solubilized mitogenic activity, 
indicating that cleavage of the glycosidic bonds of 
sulfated glycosaminoglycans released the mitogen from 
heparan sulfate proteoglycans and/or the mitogen­
proteoglycan complex from the membrane surface. 3) 
Treatment of axolemma with heparin solubilized mitogenic 
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activity, indicating that heparin (which is highly sulfated 
and thus negatively charged), chelated the (positively 
charged) mitogen from the sulfated heparan sulfate 
proteoglycans and/or displaced the mitogen-proteoglycan 
complex from the membrane surface. 
Solubilization of the mitogenic activity from axolemma 
using heparin provides us with additional information about 
the molecular nature of the mitogen. As shown in Table 4, 
about 15% of the mitogenic activity of axolemma for Schwann 
cells was solubilized using heparin; the heparin treated 
pellet was still mitogenic. We found that heparin treated 
pellets re-extracted w1th heparin lost little of their 
mitogenic activity, and that these additional heparin 
extracts contained only small amounts of protein and 
mitogenic activity. It therefore seems that most of the 
heparin-extractable mitogenicity can be removed from 
axolemma by one treatment. This provides us with two 
possibilities to explain the mi togenic 
axolemma: 1) · axolemma contains more than 
activity 
one type 
of 
of 
mitogen molecule for Schwann cells, one which is heparin 
extractable and one which is not or 2) axolemma contains 
only one type of mitogen molecule for Schwann cells, but 
some of these molecules are associated with heparin 
displaceable proteoglycans, and some associated with 
proteoglycans anchored in the lipid bilayer of the axon 
plasma membrane. Studies by Kjellen et al. (1980, 1981) 
have demonstrated that both heparin displaceable and 
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anchored proteoglycans can exist on the same tissue 
surface. 
identified, 
Proteoglycans of neuronal origin have been 
and these proteoglycans seem to be 
predominantly linked to heparan sulfate (Lander et al., 
1982; Hampson et al. , 1984; Maresh et al. , 1984; Morris, 
1984). Anchored proteoglycans may be displaced by limited 
trypsin cleavage at the membrane surface (Kjellen et al., 
1981). It would be of interest to determine if this type 
of treatment could remove heparin resistant mitogenic 
activity from the axolemmal surface. 
We have presented evidence which supports the m�del of 
a positively charged mitogen for Schwann cells associated 
with the negative charge of sulfated proteoglycans at the 
axolemmal surface. Solubilization of the mitogen has been 
achieved using heparitinase and heparin. Heparin appears 
to offer a preferable way of isolating the axolemmal 
mitogen for Schwann cells, since heparin-treated axolemma 
results in isolation of a soluble extract which has a 
higher specific mitogenic activity than the recovered· 
pellet and the untreated axolemma. Preliminary evidence 
from gel electrophoresis of this soluble mitogenic extract 
showed one protein band which appeared greatly enriched 
compared to the recovered pellet. 
Isolation of the axonal mitogen for Schwann cells using 
monoclonal antibodies: 
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Two properties of the mitogenic heparin extract 
prompted us to use this extract to raise monoclonal 
antibodies against the axolemmal mitogen for Schwann cells. 
1) The heparin extract was higher in specific mitogenic 
activity than untreated axolemma; although not homogeneous, 
figure 12 shows that the gel electrophoresis pattern of 
heparin extract is much less complicated than untreated 
axolemma. 
advantage 
affinity 
molecule. 
2) Solubility of the heparin extract is a great 
in itself: the extract can be passed over 
columns to remove and isolate the mitogen 
As described in results, we have isolated a monoclonal 
antibody (IgM: 1A5-2G3) which inhibits the mitogenic 
effect of axolemma and heparin extract to Schwann cells. 
Comparison with a non-specific source of IgM (Sigma TEPC 
183) demonstrates that a 
inhibitory effect of 1A5-2G3 
significant portion of the 
is specific. Using 1A5-2G3 
coupled to Sepharose, one major polypeptide species can be 
removed from the heparin extract; this removal correlates 
with the loss of mitogenic activity. Nearly all mitogenic 
activity can be recovered from heparin extract interacted 
with Sigma IgM-coupled Sepharose; less than 50% is 
recovered when heparin extract is interacted with 1A5-2G3-
coupled Sepharose. The inability to bind all mitogenic 
activity to 1A5-2G3-coupled Sepharose may indicate a lack 
of antibody coupled to the resin. Alternatively, 
extract and 1A5-2G3-coupled Sepharose might need 
heparin 
to be 
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interacted for long periods of time to achieve optimal 
binding of the mitogen to the antibody. The work of 
Noronha et al. (1989) for example, indicated that antigen 
needed to be cycled through the affinity column several 
times to obtain optimal binding. 
The preliminary evidence using monoclonal antibody 
1A5-2G3 indicates that this IgM can be used as a tool for 
isolating to homogeneity the mitogenic activity of the 
heparin extract and thus elucidating the molecular identity 
of the axonal mitogen for Schwann cells. The fact that 
1A5-2G3 can inhibit 100% of the mitogenic activity of 
untreated axolem,�a at certain doses indicates that the 
axolemmal mitogen for Schwann cells may be of a single 
molecular type. Solubilization of heparin resistant 
axolemmal mitogenicity (possibly by use of trypsin a3 
mentioned above) would allow testing this hypothesis: if 
both heparin displaceable and heparin resistant mitogens 
could be bound by 1A5-2G3 coupled Sepharose, molecular 
similarities would be established. 
Removal of bound polypeptide from the 1A5-2G3-coupled 
Sepharose in an active mitogenic form is the most favorable 
condition for interpreting what has bound to the column. 
Thus far, we have only been able to achieve removal of 
affinity-bound protein by the use of urea, the denaturing 
properties of which ciften inactivates the bioactivity of 
molecules. However, by interacting 
extract with 1A5-2G3-coupled Sepharose 
mitogenic heparin 
and analyzing the 
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proteins not bound to the resin, we should be able to 
obtain important information about the molecular identity 
of the axonal mitogen for Schwann cells. Further, removal 
of the single polypeptide species from affinity-resin, even 
if denaturants must be used, should still allow analysis by 
Western blotting and N-terminal sequencing techniques to 
determine whether the axonal mitogen for Schwann cells we 
have isolated is of the group of previously known mitogenic 
factors, or is a novel protein. 
Another possible way of identifying separated protein 
trophic factors after denaturation has been outlined by 
Carnow et al. (1985) and Rudge et al. (1987). These 
investigators found that after separating neuronot=ophic 
factors by SOS-PAGE and blotting the proteins onto 
nitrocellulose, cultured neurons would preferentially 
associate with certain separated proteins of distinct 
molecular weight. This method was used to help identify 
the molecular weight of the trophic factor. In theory, 
this method might be used to identify the axonal mi togen 
for Schwann cells: separated axolemmal proteins blotted 
onto nitrocellulose might cause the association and 
proliferation of Schwann cells in distinct molecular weight 
regions, thus helping us to identify the axolemmal mitogen 
for Schwann cells. 
Relevance to CNS glial proliferation: 
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Since the axolemmal source of mitogen described in 
this work is CNS-derived, our laboratory was interested in 
determining whether heparin extract of axolemma is 
mitogenic to oligodendrocytes. Chen and Devries (1989) had 
previously shown that axolemma is mitogenic to 
oligodendrocytes. When heparin extract mitogenic to 
Schwann cells was tested on oligodendrocytes, it was found 
to cause proliferation in these eel� types as well (Chen 
and Devries, 1989a). This result indicates that the same 
or similar molecules may be mitogenic to both PNS and CNS 
glia. However, the results of Mason et al. (1989a) showed 
that plasma membrane from the CNS granule cells could cause 
Schwann cells but not oligodendrocytes to proliferate. 
Thus the PNS and CNS glia might differentially respond to a 
given membrane as a mitogen. Obviously, purification to 
homogeneity of the mitogenic molecule(s) by immune-affinity 
techniques would clarify this issue. 
Relation of autocrine growth factors to the axolemmal 
mitogen: 
Many of the previous experimental results which imply 
the axon as a direct mitogen for glial cells may need to be 
reinterpreted now that there is evidence of an autocrine 
growth factor for Schwann cells (Porter et al., 1987). 
Bunge (1987) has proposed that the axon may actually serve 
as a substrate to which a Schwann cell autocrine factor 
135 
binds. Once the autocrine factor binds to the axon, the 
axonal surface provides a mitogenic signal to Schwann 
cells. 
Many results which have been interpreted as describing 
the characteristics of the axonal mitogen for Schwann cells 
can also be concei,ed as describing the characteristics of 
an axonal "presentation factor". Heat and trypsin lability 
of the mitogenic factor in axolemma (Devries et al., 1982) 
may suggest the protein nature of an axonal mitogen, or 
alternatively, an axonal protein necessary for presentation 
of a Schwann cell autocrine factor. Salzer et al. (1980a) 
originally interpreted the recovery of mitogenic activity 
of trypsinized neurites as regeneration of the axonal 
mi togen by neuronal cells. However, in light of recent 
ideas about a Schwann cell autocrine factor, this result 
could be as well interpreted as recovery of mitogenicity 
via regeneration of a presentation factor at the neuronal 
surface which is required for binding the autocrine factor. 
The results of Ratner et al. (1985) could also be 
interpreted as heparan sulfate proteoglycans are important 
for the axonal mitogen or for the axonal presentation 
molecule which binds an autocrine factor. Either function 
of the sulfated proteoglycans would by sepported by the 
findings of Margolis and Margolis (1979) that much of the 
heparan sulfate found in the brain is attached to membranes 
in fractions that appear to be enriched in plasma 
membranes. This would be consistent with the idea that 
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heparan sulfate serves as a "presenter" on the surfaces of 
cells. Heparan sulfate has been found on the surface of 
many cell types (Kraemer, 1971; Kraemer and Smith, 1974; 
Buonassisi and Root, 1975; Akasaki et al., 1975; Underhill 
and Keller, 1977; Oldberg et al., 1977). Thus, in the case 
of axons, heparan sulfate might present a neuronal mitogen 
to Schwann cells, or alternatively, present a Schwann cell 
autocrine factor to the cells in mitogenic form. Finally, 
our results showing that a monoclonal antibody inhibits the 
mitogenicity of axolemma to Schw'ann cells (Decoster and 
Devries, 1989a) could also be explained by an antibody 
which inhibits the binding of an autocrine factor to a 
presentation molecule. 
It can be seen from the above examples that many 
descriptions of the axon containing a mitogen for Schwann 
cells could also be explained by the axon containing a 
molecule which binds autocrine factors for Schwann cells. 
It seems that the issue of axon as mitogen for Schwann 
cells or substrate for autocrine factor cannot be resolved 
until individual mitogens and their receptors are isolated. 
In this respect, isolation of nerve growth factor (NGF) and 
its receptor has provided an interesting model for how 
binding of a growth factor by one cell can permit another 
cell type to utilize the bound molecule. Johnson et al. 
(1988) have provided the model of Schwann cells making NGF 
and binding this molecule at low affinity NGF receptors. 
NGF bound by Schwann cells is then given up to the high 
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affinity NGF receptors found on axons during the process 
of axonal outgrowth in development and regeneration. The 
Schwann cell serves as a relevant substrate for NGF: 
neurons need to be attracted to Schwann cells during 
development and regeneration for ensheathment and 
myelination to occur. In a similar fashion the axon may be 
an appropriate substrate for binding a Schwann cell 
autocrine factor: Schwann cells need to proliferate in 
response to axons so that ensheathment and myelination of 
all axons can be accomplished. 
Likely molecular explanation for the axon as a mitogen 
for Schwann cell5: 
In light of the above discussion, binding of a Schwann 
cell autocrine factor to the axonal surface may explain why 
axons are mi togenic to Schwann cells. However, recent 
attempts at isolating the axonal molecule (s) involved in 
Schwann cell proliferation provide evidence that makes the 
role of an autocrine factor more difficult to envision. 
Our work at solubilizing the mitogenic activity of axolemma 
for Schwann cells (Decoster and Devries, 1988, 1989) using 
heparin indicates that molecules in solution, which were 
once associated with the axonal surface, can still provide 
a mitogenic signal to Schwann cells. The work of Ratner et 
al. (1989) has shown that the mitogenic activity of 
embryonic rat brain to Schwann cells can be extracted and 
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bound to a heparin sepharose column. The mitogenic 
activity bound to the heparin column can then be eluted 
using NaCl, indicating that the mitogen is no longer 
associated with proteoglycans. Although the molecular 
identity of this mitogenic activity is not known, it is 
difficult to envision how a soluble heparin-binding 
molecule, when added to Schwann cell cultures would help 
present an autocrine factor to these cells; as the 
molecules of a soluble extract are separated into their 
different components, the most likely explanation for their 
mitogenic activity is that they themselves are mitogens. 
The ultimate resolution of axon as mitogen proper or 
substrate for autocrine factor seems to lie in isolation of 
axonally-derived molecules of a single species. If a 
cell single molecular species can cause Schwann 
proliferation, the most likely mode is via binding to a 
receptor on the Schwann cell surface. Precedents for such 
a mechanism of action include platelet-derived growth 
factor (PDGF) which stimulates DNA synthesis and cell 
division in Swiss 3T3 cells in the absence of any other 
synergistic factor (Rozengurt, 1986). We have used a 
monoclonal antibody raised against the mitogenic heparin 
of isolating the extract to begin the preliminary steps 
axonal mi togen for Schwann cells to a 
species (Decoster and Devries, 1989a). 
antibody (1A5-2GJ), which we are using 
single 
The 
molecular 
monoclonal 
to isolate the 
axolemmal mitogen, can remove mitogenic activity from the 
soluble heparin extract. However, when 
Sepharose resins, 1A5-2G3 binds protein 
displaced by denaturants such as urea. 
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coupled to CH­
which is only 
The denaturing 
effect of urea most likely irreversibly inactivates any 
mi togenic activity of the bound protein. However, 
isolating this protein may allow N-terminal amino acid 
analysis and comparison with other known growth factors to 
determine if the axonal mitogen for Schwann cells belongs 
to a class of previously described mitogens or is novel in 
character. 
Summary: 
Using the initial model system of FITC-labelled 
axolemma to study axon-Schwann cell interactions, we came 
upon the important finding, through a control experiment, 
that pH 9 extraction of axolemma dissociates only 
nonmitogenic protein from the membrane: approximately 95% 
of the mitogenic activity for Schwann cells remains 
associated with the membrane pellet. By treating the 
axolemma with heparitinase, we obtained a soluble extract 
mitogenic to Schwann cells; this result was of significance 
in light of the drawbacks of traditional techniques using 
detergents, which were often toxic to the cells. We were 
able to obtain a soluble extract mitogenic to Schwann cells 
by treating axolemma with heparin. The heparin solubilized 
extract had a higher specific mitogenic activity than the 
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starting material. 'The results of the mitogenic behavior 
of axolemma to Schwann cells after treatments with pH 9 
buffer, heparitinase, or heparin all supported a general 
molecular model of the axonal mitogen: a positively 
charged mitogen molecule associated with the negative 
charge of sulfated proteoglycans at the axonal surface. 
Using the mitogenic heparin extract of axolemma, we 
raised and isolated a monoclonal antibody (IgM: 1A5-2G3) 
which inhibited the mitogenicity of untreated axolemma and 
the heparin extract to Schwann cells. Coupling of 1A5-2G3 
to Sepharose has allowed preliminary isolation of mitogenic 
activity from the heparin extract. Since heparin extract 
is also mitogenic to oligodendrocytes, purification of the 
axonal mitogen using immune-affinity techniques should 
clarify the differences or similarities of the 
proliferative signals which axons communicate to CNS and 
PNS glia. Determination of the molecular identity of these 
proliferative signals will help our understanding of the 
normal developmental course of nervous system function. 
Major abnormalities in the nervous may occur because 
of the effect of proliferative signals on glia. 
Neurofibromatosis would appear to involve the inappropriate 
proliferation of Schwann cells with the consequent 
formation of tumors (Schwannomas). In the case of multiple 
sclerosis, it might be the lack of oligodendrocyte 
proliferation after neuronal damage that prevents the type 
of regeneration we see Schwann cells provide to the 
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peripheral nervous system. Understanding the control of 
glial cell proliferation, which is so essential to normal 
development and regeneration of the nervous system, will 
most certainly depend on the identification of the 
molecules causing these cells to divide. 
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